<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38913598</article-id><article-id pub-id-type="pmc">PMC467095</article-id>
<article-id pub-id-type="doi">10.1080/14756366.2024.2367128</article-id><article-id pub-id-type="publisher-id">2367128</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Fluorinated indeno-quinoxaline bearing thiazole moieties as hypoglycaemic agents targeting <italic toggle="yes">&#x003b1;</italic>-amylase, and <italic toggle="yes">&#x003b1;</italic>-glucosidase: synthesis, molecular docking, and ADMET studies</article-title><alt-title alt-title-type="left-running-head">N. A. Gohar et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gohar</surname><given-names>Nirvana A.</given-names></name><xref rid="AF0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Fayed</surname><given-names>Eman A.</given-names></name><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AN0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>A. Ammar</surname><given-names>Yousry</given-names></name><xref rid="AF0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>A. Abu Ali</surname><given-names>Ola</given-names></name><xref rid="AF0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Ragab</surname><given-names>Ahmed</given-names></name><xref rid="AF0003" ref-type="aff">c</xref><xref rid="AF0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Mahfoz</surname><given-names>Amal M.</given-names></name><xref rid="AF0006" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Abusaif</surname><given-names>Moustafa S.</given-names></name><xref rid="AF0003" ref-type="aff">c</xref></contrib><aff id="AF0001"><label>a</label><institution>Department of Pharmaceutical Organic Chemistry, Modern University for Technology and Information</institution>, <city>Cairo</city>, <country>Egypt</country></aff><aff id="AF0002"><label>b</label><institution>Department of Pharmaceutical Organic Chemistry, Al-Azhar University, Nasr City</institution>, <city>Cairo</city>, <country>Egypt</country></aff><aff id="AF0003"><label>c</label><institution>Department of Chemistry, , Al-Azhar University, Nasr City</institution>, <city>Cairo</city>, <country>Egypt</country></aff><aff id="AF0004"><label>d</label><institution>Department of Chemistry, College of Science, Taif University</institution>, <city>Taif</city>, <country>Saudi Arabia</country></aff><aff id="AF0005"><label>e</label><institution>Department for Biomaterials Research, Polymer Institute of the Slovak Academy of Sciences</institution>, <city>Bratislava</city>, <country>Slovakia</country></aff><aff id="AF0006"><label>f</label><institution>Department of Pharmacology and Toxicology, , Modern University for Technology and Information</institution>, <city>Cairo</city>, <country>Egypt</country></aff></contrib-group><author-notes><fn id="AUFN1"><p>Supplemental data for this article can be accessed online at <ext-link xlink:href="10.1080/14756366.2024.2367128" ext-link-type="doi">https://doi.org/10.1080/14756366.2024.2367128</ext-link>.</p></fn><corresp id="AN0001">CONTACT Eman A. Fayed <email xlink:href="mailto:alfayed_e@azhar.edu.eg">alfayed_e@azhar.edu.eg</email>
<email xlink:href="mailto:alfayed_e@yahoo.com">alfayed_e@yahoo.com</email>
<institution>Department of Pharmaceutical Organic Chemistry, Al-Azhar University, Nasr City</institution> , <city>Cairo</city>, <country>Egypt</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>24</day><month>6</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>6</month><year>2024</year></pub-date><volume>39</volume><issue>1</issue><elocation-id>2367128</elocation-id><pub-history><event event-type="received"><date><day>13</day><month>11</month><year>2023</year></date></event><event event-type="revised"><date><day>11</day><month>5</month><year>2024</year></date></event><event event-type="accepted"><date><day>6</day><month>6</month><year>2024</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>21</day><month>6</month><year>2024</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>21</day><month>6</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2024 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_39_2367128.pdf"/><abstract><title>Abstract</title><p>Inhibition of &#x003b1;-glucosidase and <italic toggle="yes">&#x003b1;</italic>-amylase are key tactics for managing blood glucose levels. Currently, stronger, and more accessible inhibitors are needed to treat diabetes. Indeno[1,2-<italic toggle="yes">b</italic>] quinoxalines-carrying thiazole hybrids <bold>1&#x02013;17</bold> were created and described using NMR. All analogues were tested for hypoglycaemic effect against STZ-induced diabetes in mice. Compounds <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> were the most potent among the synthesised analogues. These hybrids were examined for their effects on plasma insulin, urea, creatinine, GSH, MDA, ALT, AST, and total cholesterol. Moreover, these compounds were tested against <italic toggle="yes">&#x003b1;</italic>-glucosidase and <italic toggle="yes">&#x003b1;</italic>-amylase enzymes <italic toggle="yes">in vitro</italic>. The four hybrids <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> represented moderate to potent activity with IC<sub>50</sub> values 0.982&#x02009;&#x000b1;&#x02009;0.04, to 10.19&#x02009;&#x000b1;&#x02009;0.21 for <italic toggle="yes">&#x003b1;</italic>-glucosidase inhibition and 17.58&#x02009;&#x000b1;&#x02009;0.74 to 121.6&#x02009;&#x000b1;&#x02009;5.14&#x02009;&#x003bc;M for <italic toggle="yes">&#x003b1;</italic>-amylase inhibition when compared to the standard medication acarbose with IC<sub>50</sub>=0.316&#x02009;&#x000b1;&#x02009;0.02 &#x003bc;M for <italic toggle="yes">&#x003b1;</italic>-glucosidase inhibition and 31.56&#x02009;&#x000b1;&#x02009;1.33&#x02009;&#x003bc;M for <italic toggle="yes">&#x003b1;</italic>-amylase inhibition. Docking studies as well as <italic toggle="yes">in silico</italic> ADMT were done.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><fig position="anchor" id="UF0001"><graphic xlink:href="IENZ_A_2367128_UF0001_C" content-type="color" position="float"/></fig></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd><italic toggle="yes">&#x003b1;-A</italic>mylase</kwd><kwd><italic toggle="yes">&#x003b1;</italic>-Glucosidase</kwd><kwd>Fluorinated indeno-quinoxaline</kwd></kwd-group><support-group><funding-group><funding-statement>The project has been funded by the Taif University Researchers Supporting Project (TURSP) at Taif University, Taif, Saudi Arabia, under Grant (TURSP-2020/220). The authors extend their appreciation to Tife University, Saudi Arabia, for supporting this work through project number (TU-DSPP-2024-85).</funding-statement></funding-group></support-group><counts><fig-count count="7"/><table-count count="13"/><page-count count="16"/><word-count count="8631"/></counts></article-meta></front><body><sec sec-type="intro" disp-level="1" id="S0001"><title>Introduction</title><p>Diabetes mellitus (DM) is becoming more and more prevalent all over the world. DM is a long-term metabolic disorder that happens when the pancreas does not make enough insulin, or the body doesn&#x02019;t use it adequately<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. Almost 463 million people are affected by it globally, and by 2030, that number is predicted to reach 578 million<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. Diabetes mellitus is a collection of metabolic illnesses defined by hyperglycaemia resulting from abnormalities in insulin secretion, insulin action, or both. Diabetes&#x02019;s chronic hyperglycaemia is linked to long-term harm, malfunction, and organ failure, particularly to the kidneys, eyes, heart, nerves, and blood vessels. Type II diabetes, or non-insulin-dependent diabetes mellitus (NIDDM), is characterised by impaired glucose homeostasis that leads to hyperglycaemia and is linked to neuropathy, macrovascular, and microvascular problems. NIDDM is a multifactorial, intricate disease<xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref>.</p><p>Long-term diabetes can result in numerous problems, including alterations to the blood vessels and cellular malfunction. Proteinuria, a steady loss in renal and hepatic functioning, and a higher risk of cardiovascular illnesses are all clinical symptoms of diabetes mellitus. Persistent hyperglycaemia boosts the formation of free radicals and weakens intracellular antioxidant defences, which causes oxidative stress and the activation of apoptotic pathways. This, in turn, controls the generation of several pro-inflammatory mediators that worsen damage to different organs and impair the course of diabetes mellitus<xref rid="CIT0004" ref-type="bibr"><sup>4&#x02013;7</sup></xref>. Thus, creating new, safe, and biologically active anti-diabetic drugs is crucial.</p><p>Preventing problems from diabetes brought on by non-enzymatic glycation and the inhibition of blood glucose-regulating enzymes is the main objective of treatment for diabetes. The generation of insulin by pancreatic islets regulates this scenario. Furthermore, enzymes like <italic toggle="yes">&#x003b1;</italic> -glucosidase and <italic toggle="yes">&#x003b1;</italic> -amylase are employed to halt the decomposition of sugar<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>. Therefore, the inhibition of <italic toggle="yes">&#x003b1;</italic> -glucosidase is a major scientific focus for hyperglycaemic control in diabetic patients. Intestinal <italic toggle="yes">&#x003b1;</italic> -glucosidases break down dietary carbs into simple sugars so that they can be absorbed<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>. Inhibiting intestinal <italic toggle="yes">&#x003b1;</italic>-glucosidase is one approach of inhibiting carbohydrate breakdown and limiting carbohydrate absorption in diabetes to reduce hyperglycaemia. According to this strategy, acarbose, miglitol, and voglibose were produced as anti-diabetic medications a few years ago. However, since then, no significant development has been made in developing new <italic toggle="yes">&#x003b1;</italic>-glucosidase inhibitors as diabetic medications with enhanced effectiveness and fewer adverse effects<xref rid="CIT0010" ref-type="bibr"><sup>10</sup></xref>. To improve this area of anti-diabetic treatment, there is still a critical necessity to find novel <italic toggle="yes">&#x003b1;</italic> -glucosidase inhibitors to improve the activity and decrease the adverse side effects.</p><p>Moreover, the metallo-enzyme <italic toggle="yes">&#x003b1;</italic>-amylase is a member of the endo-amylase family and is responsible for catalysing the first step of starch hydrolysis into shorter oligosaccharides by cleaving <italic toggle="yes">&#x003b1;</italic>-D-(1&#x02013;4) glycosidic linkages as it contains Ca2+ ions in its active site. Due to its ability to hydrolyse the 1,4-glycosidic linkage of starch and the actions that can be carried out because of hydrolysis, this enzyme attracted great interest. The use of a lot of carbohydrates is linked to certain major issues such as obesity, diabetes, and dental diseases<xref rid="CIT0011" ref-type="bibr"><sup>11&#x02013;14</sup></xref>.</p><p>Additionally, a wide variety of biological properties, for example anti-inflammatory, antibacterial, anti-cancer, and antioxidant ones, are displayed by thiazole derivatives<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref>. In addition, they have been revealed to have effective &#x003b1;-glucosidase inhibitory action. Some examples of this activity include the thiazole derivatives isatin-thiazole<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>, coumarin-thiazole<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>, thiazole-pyrrole<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref>, and triazine-thiazole<xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>. There is an insufficient amount of research available regarding the impact of isomerism on the inhibition of <italic toggle="yes">&#x003b1;</italic>-glucosidase, but those that do include research on kotalanol, iminosugars, hyacinthacins, bicyclitols, bicyclitol-deoxynojirimycin conjugates, perylene bisimide-deoxynojirimycin conjugates, perylene bisimide-deoxynojirimycin conjugates<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>.</p><p>The current research is a part of our ongoing search for the discovery of novel hybrids to treat different diseases<xref rid="CIT0022" ref-type="bibr"><sup>22&#x02013;27</sup></xref>. Herein we synthesised <italic toggle="yes">&#x003b1;</italic>-glucosidase and <italic toggle="yes">&#x003b1;</italic>-amylase inhibitors that might be used in the development of anti-diabetic medications (<xref rid="F0001" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F0001"><label>Figure 1.</label><caption><p>Synthetic approach for designing indenoquinoxaline hits <bold>3&#x02013;17</bold>.</p></caption><graphic xlink:href="IENZ_A_2367128_F0001_C" content-type="color" position="float"/></fig><fig position="float" id="SCH0001"><label>Scheme 1.</label><caption><p>Illustrate the synthesis of indeno-quinoxaline derivative <bold>3</bold> and synthesis of new Schiff&#x02019;s base derivatives <bold>4&#x02013;6</bold>.</p></caption><graphic xlink:href="IENZ_A_2367128_SCH0001_C" content-type="color" position="float"/></fig><fig position="float" id="SCH0002"><label>Scheme 2.</label><caption><p>Strategy for the synthesis of hydrazone derivatives <bold>7&#x02013;9</bold>.</p></caption><graphic xlink:href="IENZ_A_2367128_SCH0002_C" content-type="color" position="float"/></fig></sec><sec sec-type="materials" disp-level="1" id="S0002"><title>Materials and methods</title><p>S1 in the <ext-link xlink:href="10.1080/14756366.2024.2367128" ext-link-type="doi">supplementary materials</ext-link><xref rid="CIT0028" ref-type="bibr"><sup>28&#x02013;49</sup></xref>.</p></sec><sec sec-type="results" disp-level="1" id="S0003"><title>Result and discussion</title><sec disp-level="2" id="S0003-S2001"><title>Chemistry</title><p>All the target substances were successfully synthesised according to <xref rid="SCH0001 SCH0002 SCH0003" ref-type="fig">Scheme 1&#x02013;3</xref>, and their predicted structures were validated using analytical and spectroscopic data (IR,<sup>1</sup>H NMR,<sup>13</sup>C NMR). According to the literature protocol<xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref>, 7-fluoro-11<italic toggle="yes">H</italic>-indeno[1,2-<italic toggle="yes">b</italic>]quinoxalin-11-one (<bold>3</bold>) is prepared as a starting compound by cyclo-condensation of 4-fluoro-1,2-phenylenediamine (<bold>1</bold>) with ninhydrin <bold>2</bold> in hot methanol and catalytic quantities of acetic acid. Due to the importance of the biological activity of thiazole moiety, the author planned to design and construct a thiazole ring linked with the starting material <bold>3</bold>
<italic toggle="yes">via</italic> keto function (C&#x02009;=&#x02009;O).</p><p>As viewed in <xref rid="SCH0001" ref-type="fig">Scheme 1</xref>, the starting material fluoro-indenoquinoxaline (<bold>1)</bold> was subjected to react with 2-aminothiazol derivatives specified, 2-aminothiazol-4(5<italic toggle="yes">H</italic>)-one, 1&#x02013;(2-amino-4-methylthiazol-5-yl)ethan-1-one or ethyl 2-amino-4-methylthiazole-5-carboxylate via a condensation reaction to afford the corresponding imine thiazole derivatives <bold>4&#x02013;6</bold>. The spectral data confirmed the expected structure of the products. The IR spectrum of compound <bold>4</bold> indicates the presence of one carbonyl group at 1736&#x02009;cm<sup>&#x02212;1</sup> and the imino function C&#x02009;=&#x02009;N at 1604&#x02009;cm<sup>&#x02212;1</sup>. Additionally, its <sup>1</sup>H NMR spectra designates two aliphatic protons of CH<sub>2</sub> at <italic toggle="yes">&#x003b4;</italic> 4.08&#x02009;ppm beside the aromatic protons ranging from <italic toggle="yes">&#x003b4;</italic> 7.69&#x02013;8.24&#x02009;ppm. The<sup>13</sup>C NMR spectrum revealed the aliphatic CH<sub>2</sub> of the thiazolone ring at <italic toggle="yes">&#x003b4;</italic> 37.46&#x02009;ppm, the aromatic carbons ranged from <italic toggle="yes">&#x003b4;</italic> 113.94&#x02013;145.60&#x02009;ppm, C&#x02009;=&#x02009;N at <italic toggle="yes">&#x003b4;</italic> 163.57&#x02009;ppm, carbonyl at <italic toggle="yes">&#x003b4;</italic> 178.41, and signals at <italic toggle="yes">&#x003b4;</italic> 179.02&#x02009;ppm due to S-C&#x02009;=&#x02009;N function. Also, the IR spectrum of compound <bold>5</bold> revealed an absorption band at 1735&#x02009;cm<sup>&#x02212;1</sup> corresponding to the carbonyl group due to acetyl thiazole, while compound <bold>6</bold> presented absorption bands for CH aromatic, CH aliphatic, C&#x02009;=&#x02009;O, and C&#x02009;=&#x02009;N groups at 3076, 2925, 1735, 1605&#x02009;cm<sup>&#x02212;1</sup> respectively. The <sup>1</sup>H NMR compound <bold>5</bold> demonstrated two singlet signals at <italic toggle="yes">&#x003b4;</italic> 2.33, and 2.41&#x02009;ppm relevant to the two methyl protons, as well as signals for the aromatic protons between <italic toggle="yes">&#x003b4;</italic> 7.72&#x02009;ppm to <italic toggle="yes">&#x003b4;</italic> 8.25&#x02009;ppm, while compound <bold>6</bold> displayed signals at <italic toggle="yes">&#x003b4;</italic> 1.21, 2.38, and 4.13&#x02009;ppm for two CH<sub>3</sub> and CH<sub>2</sub> of the ethyl group beside the signals of the aromatic protons. The<sup>13</sup>C NMR of compound <bold>5</bold> characterised the structure by the presence of two signals for aliphatic carbons, signals for aromatic carbons, and signals for (C-F), and (C&#x02009;=&#x02009;O) groups.</p><fig position="float" id="SCH0003"><label>Scheme 3.</label><caption><p>Proposed reactions for the synthesis of arylidine-indenoquinoxaline derivatives <bold>10</bold>, <bold>12</bold>, and <bold>13</bold>.</p></caption><graphic xlink:href="IENZ_A_2367128_SCH0003_C" content-type="color" position="float"/></fig><p>By the same manner, 7-fluoro-11<italic toggle="yes">H</italic>-indeno[1,2-<italic toggle="yes">b</italic>]quinoxalin-11-one (<bold>3</bold>) was allowed to react with some thiazolyl hydrazines such as 2-hydrazineylthiazol-4(5<italic toggle="yes">H</italic>)-one, 1&#x02013;(2-hydrazineyl-4-methylthiazol-5-yl)ethan-1-one, or ethyl 2-hydrazineyl-4-methylthiazole-5-carboxylate, respectively, to produce the corresponding hydrazone derivatives <bold>7&#x02013;9</bold>, <xref rid="SCH0002" ref-type="fig">Scheme 2</xref>. The IR spectrum of compound <bold>7</bold> revealed bands at 3130, 3049, 2967, 1709, and 1612&#x02009;cm<sup>&#x02212;1</sup> corresponding to NH, CH-aromatic, CH-aliphatic, carbonyl, and imino (C&#x02009;=&#x02009;N) groups, respectively. Moreover, its <sup>1</sup>H NMR displayed a singlet signal at <italic toggle="yes">&#x003b4;</italic> 4.06&#x02009;ppm due to CH<sub>2</sub> aliphatic protons of thiazolone and one singlet signal at <italic toggle="yes">&#x003b4;</italic> 11.77&#x02009;ppm for NH beside the aromatic protons. Also, <sup>13</sup>C NMR confirmed the reaction product by the presence of a signal at <italic toggle="yes">&#x003b4;</italic> 33.03&#x02009;ppm related to CH<sub>2</sub> of aliphatic carbon, and twelve signals for the aromatic carbons beside the signals specific to C&#x02009;=&#x02009;N, C-F, and carbonyl carbons at <italic toggle="yes">&#x003b4;</italic> 160.05, 162.35, and 168.75&#x02009;ppm, respectively. The IR spectrum of compound <bold>8</bold> displayed an absorption band at 3427 attributed to (NH), and a band at 1735&#x02009;cm<sup>&#x02212;1</sup> due to (C&#x02009;=&#x02009;O). Moreover, its <sup>1</sup>H NMR spectrum displayed two singlet signals at <italic toggle="yes">&#x003b4;</italic> 1.94 and 2.29&#x02009;ppm because of the presence of two methyl groups, a singlet signal at <italic toggle="yes">&#x003b4;</italic> 7.96&#x02009;ppm related to the NH group along with seven aromatic protons between <italic toggle="yes">&#x003b4;</italic> 7.72 to 8.23&#x02009;ppm, while <sup>1</sup>H NMR spectrum of compound <bold>9</bold> revealed three signals as triplet, singlet, and quartette splitting signals at <italic toggle="yes">&#x003b4;</italic> 1.27, 2.57, 4.23&#x02009;ppm which represent the aliphatic protons of methyl and ethyl groups in addition to aromatic protons and the proton of the NH group which appeared at <italic toggle="yes">&#x003b4;</italic> 7.90&#x02009;ppm. Also, the <sup>13</sup>C NMR spectrum of compound <bold>9</bold> displayed the existence of three carbons at <italic toggle="yes">&#x003b4;</italic> 19.23, 21.02, and 61.94&#x02009;ppm assignable for methyl and ethyl carbons in addition to the signals of the aromatic carbons and the signals representing (C&#x02009;=&#x02009;N), carbon attached to fluoride (C-F), (S-C&#x02009;=&#x02009;N), and carbonyl (C&#x02009;=&#x02009;O).</p><fig position="float" id="SCH0004"><label>Scheme 4.</label><caption><p>Synthesis of thiosemicarbazone derivative <bold>14</bold> and its cyclisation to afford the thiazole derivatives <bold>15&#x02013;17</bold>.</p></caption><graphic xlink:href="IENZ_A_2367128_SCH0004_C" content-type="color" position="float"/></fig><p>2-Hydrazineylthiazol-4(5<italic toggle="yes">H</italic>)-one has two nucleophilic active centres, hydrazine function and methylene CH<sub>2</sub> function. The condensation of the keto group with hydrazine function in acidic medium afforded the corresponding hydrazone, while its condensation with methylene CH<sub>2</sub> function in a basic medium, afforded the corresponding arylidine derivatives (C&#x02009;=&#x02009;C). Therefore, the starting material <bold>3</bold> was condensed with 2-hydrazineylthiazol-4(5<italic toggle="yes">H</italic>)-one in a basic medium using freshly prepared fused sodium acetate to produce the target 5&#x02013;(7-fluoro-11<italic toggle="yes">H</italic>-indeno[1,2-<italic toggle="yes">b</italic>]quinoxalin-11-ylidene)-2-hydrazineylthiazol-4(5<italic toggle="yes">H</italic>)-one (<bold>10</bold>), <xref rid="SCH0003" ref-type="fig">Scheme 3</xref>. Elemental analysis and spectrum data proved the product. Along with a carbonyl band at 1711&#x02009;cm<sup>&#x02212;1</sup>, IR spectra showed NH<sub>2</sub> and NH bands at 3415 and 3190&#x02009;cm<sup>&#x02212;1</sup>. Aside from two signals that emerged at <italic toggle="yes">&#x003b4;</italic> 5.43 and 7.89&#x02009;ppm due to NH<sub>2</sub> and NH, <sup>1</sup>H NMR also showed signals caused by aromatic protons. In addition to signals for the aromatic carbons, its <sup>13</sup>C NMR provided signals at <italic toggle="yes">&#x003b4;</italic> 172.16 for the carbonyl group, 161.58&#x02009;ppm for carbon attached to fluoride atom, <italic toggle="yes">&#x003b4;</italic> 158.91 for (S-C&#x02009;=&#x02009;N), and 157.13&#x02009;ppm for (C&#x02009;=&#x02009;N) groups. Also as viewed in <xref rid="SCH0003" ref-type="fig">Scheme 3</xref>, the two reagents <bold>11a</bold> and <bold>11b</bold> were prepared according to previous work <xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="CIT0052" ref-type="bibr"><sup>52</sup></xref>, and allowed to react with the starting material <bold>3</bold> in a basic medium using freshly prepared fused sodium acetate to produce the corresponding <bold>12</bold> and <bold>13</bold>. The structure of <bold>12</bold> was confirmed by microanalyses and spectral data. The IR spectrum exhibited a band at 3422&#x02009;cm<sup>&#x02212;1</sup> related to the NH group in addition to the carbonyl band at 1729&#x02009;cm<sup>&#x02212;1</sup>. The <sup>1</sup>H NMR spectrum of the same compound showed the exchangeable signal of the NH group at <italic toggle="yes">&#x003b4;</italic> 8.90&#x02009;ppm and the signals for seventeen aromatic protons. Furthermore, its <sup>13</sup>C NMR indicated three signals at <italic toggle="yes">&#x003b4;</italic> 164.99, 172.31, and 174.44&#x02009;ppm for S-C&#x02009;=&#x02009;N, C-F, and C&#x02009;=&#x02009;O groups, besides the aromatic carbons. Also, the <sup>1</sup>H NMR spectrum of compound <bold>13</bold> elicited two singlet signals at <italic toggle="yes">&#x003b4;</italic> 10.67 and 11.05&#x02009;ppm attributed to 2NH protons, besides the signals associated with the aromatic Hs. Additionally, <sup>13</sup>C NMR presented signals between <italic toggle="yes">&#x003b4;</italic> 110.29 to 157.24&#x02009;ppm, and four signals at <italic toggle="yes">&#x003b4;</italic> 164.97, 168.86, 171.92, and 171.97&#x02009;ppm related to (S-C&#x02009;=&#x02009;N), (C-F), and (2&#x02009;C&#x02009;=&#x02009;O) groups correspondingly.</p><p>Thiosemicarbazone derivatives are very useful and widely used as a synthetic initial compound for thiazole synthesis. Consequently, compound <bold>3</bold> was allowed to react with thiosemicarbazide to produce the corresponding thiosemicarbazone derivative <bold>14</bold>, <xref rid="SCH0004" ref-type="fig">Scheme 4</xref>. Its IR spectrum doesn&#x02019;t have the C&#x02009;=&#x02009;O group absorption band present in compound <bold>3</bold> and at the same time revealed NH<sub>2</sub> and NH group absorption bands at 3448, 3396, and 3275&#x02009;cm<sup>&#x02212;1</sup> respectively. The <sup>1</sup>H NMR spectrum exhibited two singlet signals at <italic toggle="yes">&#x003b4;</italic> 8.15, and 12.48&#x02009;ppm relevant to the NH<sub>2</sub>, and NH protons together with signals related to the aromatic protons. Furthermore, thiosemicarbazone derivative <bold>14</bold> was cyclo-alkylated to obtain many biologically active thiazole compounds. Thus, the interaction of compound <bold>14</bold> with an alkylating agent (ethyl 2-chloropropanoate, ethyl 2-chlorobutanoate) or diethyl but-2-ynedioate produced the corresponding different derivatives <bold>15&#x02013;17</bold>, <xref rid="SCH0004" ref-type="fig">Scheme 4</xref>. The IR spectrum of compound <bold>15</bold> exhibited bands at 3396&#x02009;cm<sup>&#x02212;1</sup> for the NH<sub>2</sub> group, and 1722&#x02009;cm<sup>&#x02212;1</sup> due to the C&#x02009;=&#x02009;O group. The <sup>1</sup>H NMR field confirmed its structure through the appearance of a singlet signal at <italic toggle="yes">&#x003b4;</italic> 1.45&#x02009;ppm corresponding to the hydrogens of the methyl, a quartette signal at <italic toggle="yes">&#x003b4;</italic> 3.81&#x02009;ppm representing CH of thiazolone, signals in the region <italic toggle="yes">&#x003b4;</italic> 7.54&#x02013;8.26&#x02009;ppm showing the aromatic protons, in addition to singlet signal at <italic toggle="yes">&#x003b4;</italic> 8.84&#x02009;ppm due to NH group. While the <sup>1</sup>H NMR spectrum of <bold>16</bold> displayed a triplet signal at <italic toggle="yes">&#x003b4;</italic> 0.99 due to (<underline>CH<sub>3</sub></underline>-CH<sub>2</sub>), a signal at <italic toggle="yes">&#x003b4;</italic> 2.02&#x02009;ppm corresponding to (CH<sub>3</sub>-<underline>CH<sub>2</sub></underline>), triplet signal at <italic toggle="yes">&#x003b4;</italic> 4.33 assignable to the CH in the thiazole, and a singlet signal at <italic toggle="yes">&#x003b4;</italic> 12.64 for the NH group beside the signals of the aromatic protons. The <sup>13</sup>C NMR spectrum showed the presence of two aliphatic carbons at <italic toggle="yes">&#x003b4;</italic> 19.85, and 57.87&#x02009;ppm, whereas the carbon attached to the flour and the carbonyl carbon were observed at <italic toggle="yes">&#x003b4;</italic> 154.29, and 178.79&#x02009;ppm respectively. Finally, The IR spectrum of thiazolone derivative <bold>17</bold> displayed absorption bands at 3263, 1727, and 1700&#x02009;cm<sup>&#x02212;1</sup> related to NH, and two carbonyl groups respectively. Also, its <sup>1</sup>H NMR spectrum revealed two signals at <italic toggle="yes">&#x003b4;</italic> 1.27, and 4.24&#x02009;ppm due to the ethyl group, besides a signal at <italic toggle="yes">&#x003b4;</italic> 6.64&#x02009;ppm for the CH-vinilic, and a signal at <italic toggle="yes">&#x003b4;</italic> 7.98&#x02009;ppm for the NH group, in addition to the aromatic protons. <sup>13</sup>C NMR spectrum was characterised by signals at <italic toggle="yes">&#x003b4;</italic> 14.57, 61.55, and 96.97&#x02009;ppm representing the two aliphatic carbons of the ethyl group, and CH-vinylic, as well as signals at <italic toggle="yes">&#x003b4;</italic> 158.28, 161.62, 165.01&#x02009;ppm related to (C&#x02009;=&#x02009;N), (S-C&#x02009;=&#x02009;N), (C-F) carbons, and two signals at <italic toggle="yes">&#x003b4;</italic> 166.24, 166.38&#x02009;ppm assignable to (2&#x02009;C&#x02009;=&#x02009;O) groups besides signals in the aromatic region owing to the aromatic carbons.</p></sec><sec disp-level="2" id="S0003-S2002"><title>Biology</title><sec disp-level="3" id="S0003-S2002-S3001"><title>Blood glucose and plasma insulin level</title><p>Streptozotocin (STZ) causes a significant increase in blood sugar and a big drop in insulin levels in the plasma. When gliclazide and the newly synthesised hybrids were used, blood sugar levels declined significantly, and insulin levels rose compared to the STZ-only treatment group (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05) (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="t0001"><label>Table 1.</label><caption><p>Effect of two weeks of treatment with new hybrids <bold>4&#x02013;17</bold> as well as Gliclazide on plasma glucose and insulin level in STZ-induced diabetes in mice.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Parameters Groups</th><th align="center">Glucose 3<sup>rd</sup> day (mg/dL)</th><th align="center">Glucose 6<sup>th</sup> day</th><th align="center">Glucose 9<sup>th</sup> day</th><th align="center">Glucose 12<sup>th</sup> day</th><th align="center">Glucose 15<sup>th</sup> day</th><th align="center">Insulin (ng/mL)</th></tr></thead><tbody valign="top"><tr><td align="left">NC</td><td align="char" char=".">98.67&#x02009;&#x000b1;&#x02009;4.4<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">98.67&#x02009;&#x000b1;&#x02009;4.4<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">98.67&#x02009;&#x000b1;&#x02009;4.4<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">98.67&#x02009;&#x000b1;&#x02009;4.4<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">98.67&#x02009;&#x000b1;&#x02009;4.4<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">16.75&#x02009;&#x000b1;&#x02009;0.5<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td align="left">PC</td><td align="char" char=".">279.17&#x02009;&#x000b1;&#x02009;10.2<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">357.50&#x02009;&#x000b1;&#x02009;18.96<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">540&#x02009;&#x000b1;&#x02009;26.6<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" char=".">519.17&#x02009;&#x000b1;&#x02009;27.8<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" char=".">486.67&#x02009;&#x000b1;&#x02009;11.4<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" char=".">3.14&#x02009;&#x000b1;&#x02009;0.2<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td align="left">Gliclazide</td><td align="char" char=".">358.33&#x02009;&#x000b1;&#x02009;18.1<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">199.67&#x02009;&#x000b1;&#x02009;5.8</td><td align="char" char=".">165&#x02009;&#x000b1;&#x02009;4.1<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">132.33&#x02009;&#x000b1;&#x02009;3.7<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">118.33&#x02009;&#x000b1;&#x02009;3.3<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">14.52&#x02009;&#x000b1;&#x02009;0.4<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left">4</td><td align="char" char=".">311.33&#x02009;&#x000b1;&#x02009;19.5<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">293.33&#x02009;&#x000b1;&#x02009;17.8<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">304.17&#x02009;&#x000b1;&#x02009;7.1<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">187&#x02009;&#x000b1;&#x02009;3.4<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">162.83&#x02009;&#x000b1;&#x02009;1.8&#x02009;b</td><td align="char" char=".">11.44&#x02009;&#x000b1;&#x02009;0.2<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left">5</td><td align="char" char=".">436.67&#x02009;&#x000b1;&#x02009;51.6<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">566.67&#x02009;&#x000b1;&#x02009;15.4<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" char=".">251.67&#x02009;&#x000b1;&#x02009;13.5<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">300&#x02009;&#x000b1;&#x02009;18.2<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">256.67&#x02009;&#x000b1;&#x02009;19.9<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="left">&#x000a0;</td></tr><tr><td align="left">6</td><td align="char" char=".">332.50&#x02009;&#x000b1;&#x02009;18.4<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">363.83&#x02009;&#x000b1;&#x02009;69<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">220&#x02009;&#x000b1;&#x02009;13.9<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">177.50&#x02009;&#x000b1;&#x02009;3.8<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">155.67&#x02009;&#x000b1;&#x02009;3.6<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">12.28&#x02009;&#x000b1;&#x02009;0.3<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left">7</td><td align="char" char=".">478.33&#x02009;&#x000b1;&#x02009;44.7<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">543.33&#x02009;&#x000b1;&#x02009;17.6<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" char=".">280.83&#x02009;&#x000b1;&#x02009;27.5<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">230&#x02009;&#x000b1;&#x02009;9.3<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">216.67&#x02009;&#x000b1;&#x02009;10.6<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="left">&#x000a0;</td></tr><tr><td align="left">8</td><td align="char" char=".">313.33&#x02009;&#x000b1;&#x02009;4.9<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">238.33&#x02009;&#x000b1;&#x02009;4.8</td><td align="char" char=".">202.50&#x02009;&#x000b1;&#x02009;3.6<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">214.83&#x02009;&#x000b1;&#x02009;9.97<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">175&#x02009;&#x000b1;&#x02009;11.5<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">10.5&#x02009;&#x000b1;&#x02009;0.3<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left">9</td><td align="char" char=".">321.67&#x02009;&#x000b1;&#x02009;35.5<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">300.83&#x02009;&#x000b1;&#x02009;34.7<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">275.17&#x02009;&#x000b1;&#x02009;24<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">355&#x02009;&#x000b1;&#x02009;18.4<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" char=".">337.17&#x02009;&#x000b1;&#x02009;11.4<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="left">&#x000a0;</td></tr><tr><td align="left">10</td><td align="char" char=".">385.83&#x02009;&#x000b1;&#x02009;61.2<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">381.67&#x02009;&#x000b1;&#x02009;23.3<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">305.33&#x02009;&#x000b1;&#x02009;16.4<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">408.33&#x02009;&#x000b1;&#x02009;40.3<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" char=".">368.33&#x02009;&#x000b1;&#x02009;33<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="left">&#x000a0;</td></tr><tr><td align="left">12</td><td align="char" char=".">343.00&#x02009;&#x000b1;&#x02009;52.8<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">288.33&#x02009;&#x000b1;&#x02009;77.9</td><td align="char" char=".">332.17&#x02009;&#x000b1;&#x02009;79.1<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">251.67&#x02009;&#x000b1;&#x02009;60.8<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">325&#x02009;&#x000b1;&#x02009;15.6<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="left">&#x000a0;</td></tr><tr><td align="left">13</td><td align="char" char=".">340.83&#x02009;&#x000b1;&#x02009;39.2<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">240&#x02009;&#x000b1;&#x02009;54.2</td><td align="char" char=".">295&#x02009;&#x000b1;&#x02009;80.3<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">226.67&#x02009;&#x000b1;&#x02009;48.6<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">225&#x02009;&#x000b1;&#x02009;46.7<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="left">&#x000a0;</td></tr><tr><td align="left">14</td><td align="char" char=".">351.67&#x02009;&#x000b1;&#x02009;16.6<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">258.33&#x02009;&#x000b1;&#x02009;16.6</td><td align="char" char=".">213&#x02009;&#x000b1;&#x02009;10.3<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">387.50&#x02009;&#x000b1;&#x02009;82.7<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" char=".">320.50&#x02009;&#x000b1;&#x02009;79.9<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="left">&#x000a0;</td></tr><tr><td align="left">15</td><td align="char" char=".">321.67&#x02009;&#x000b1;&#x02009;24.7<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">356.67&#x02009;&#x000b1;&#x02009;29.6<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">294.17&#x02009;&#x000b1;&#x02009;31.3<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">318.33&#x02009;&#x000b1;&#x02009;27.7<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" char=".">294.17&#x02009;&#x000b1;&#x02009;31.3<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="left">&#x000a0;</td></tr><tr><td align="left">16</td><td align="char" char=".">313.33&#x02009;&#x000b1;&#x02009;23.8<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">254.50&#x02009;&#x000b1;&#x02009;9.7</td><td align="char" char=".">217.50&#x02009;&#x000b1;&#x02009;6.3<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">202&#x02009;&#x000b1;&#x02009;13.5<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">169&#x02009;&#x000b1;&#x02009;1.5<xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">9.34&#x02009;&#x000b1;&#x02009;0.3<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left">17</td><td align="char" char=".">410&#x02009;&#x000b1;&#x02009;57.6<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">350.83&#x02009;&#x000b1;&#x02009;80<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">294.17&#x02009;&#x000b1;&#x02009;60.9<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">323.33&#x02009;&#x000b1;&#x02009;65.2<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="char" char=".">312.50&#x02009;&#x000b1;&#x02009;63<xref rid="TF2" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF3" ref-type="table-fn"><sup>b</sup></xref><sup>,</sup><xref rid="TF4" ref-type="table-fn"><sup>c</sup></xref></td><td align="left">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>Each value represents the mean of 6 mice&#x02009;&#x000b1;&#x02009;SEM. Statistical analysis was carried out using one-way analysis of variance (ANOVA) followed by Tukey Kramer multiple comparisons test.</p></fn><fn id="TF2"><label>
<sup>a</sup>
</label><p>significantly different from normal control (NC) (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></fn><fn id="TF3"><label>
<sup>b</sup>
</label><p>significantly different from positive control (PC) (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></fn><fn id="TF4"><label>
<sup>c</sup>
</label><p>significantly different from standard (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="3" id="S0003-S2002-S3002"><title>Kidney function parameters</title><p>STZ resulted in a nephropathy state manifested by a significant elevation of plasma urea and creatinine levels as compared to normal control mice. Treatment with gliclazide and <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> led to a significant lowering in plasma urea and creatinine levels as related to STZ only treated group <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 (<xref rid="t0002" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="t0002"><label>Table 2.</label><caption><p>Effect of two weeks of treatment with <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> on plasma levels of urea, creatinine, GSH, MDA, ALT, AST, and total cholesterol in STZ-induced diabetes in mice.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Parameter Groups</th><th align="center">Urea</th><th align="center">Creat</th><th align="center">GSH</th><th align="center">MDA</th><th align="center">ALT</th><th align="center">AST</th><th align="center">TC</th></tr></thead><tbody valign="top"><tr><td align="left">NC</td><td align="char" char=".">55.1&#x02009;&#x000b1;&#x02009;0.3</td><td align="char" char=".">2.03&#x02009;&#x000b1;&#x02009;0.1</td><td align="char" char=".">4.56&#x02009;&#x000b1;&#x02009;0.02</td><td align="char" char=".">18.57&#x02009;&#x000b1;&#x02009;0.2</td><td align="char" char=".">44.4&#x02009;&#x000b1;&#x02009;0.8</td><td align="char" char=".">35.2&#x02009;&#x000b1;&#x02009;0.3</td><td align="char" char=".">65.3&#x02009;&#x000b1;&#x02009;0.4</td></tr><tr><td align="left">PC</td><td align="char" char=".">91.6&#x02009;&#x000b1;&#x02009;0.5<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">7.8&#x02009;&#x000b1;&#x02009;0.1<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">0.998&#x02009;&#x000b1;&#x02009;0.04<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">40.3&#x02009;&#x000b1;&#x02009;0.8<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">96.7&#x02009;&#x000b1;&#x02009;0.7<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">87.6&#x02009;&#x000b1;&#x02009;0.7<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref></td><td align="char" char=".">150.3&#x02009;&#x000b1;&#x02009;1<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left">Gliclazide</td><td align="char" char=".">57.5&#x02009;&#x000b1;&#x02009;0.3<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">3.3&#x02009;&#x000b1;&#x02009;0.1<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">3.15&#x02009;&#x000b1;&#x02009;0.05<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">22&#x02009;&#x000b1;&#x02009;0.2<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">53.7&#x02009;&#x000b1;&#x02009;0.7<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">39.8&#x02009;&#x000b1;&#x02009;0.3<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">74.4&#x02009;&#x000b1;&#x02009;0.6<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left">4</td><td align="char" char=".">60.5&#x02009;&#x000b1;&#x02009;0.4<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">5.1&#x02009;&#x000b1;&#x02009;0.1<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">2.17&#x02009;&#x000b1;&#x02009;0.03<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">23.9&#x02009;&#x000b1;&#x02009;0.2<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">66&#x02009;&#x000b1;&#x02009;0.4<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">46.4&#x02009;&#x000b1;&#x02009;0.2<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">79.3&#x02009;&#x000b1;&#x02009;0.4<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left">6</td><td align="char" char=".">59.5&#x02009;&#x000b1;&#x02009;0.2<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">4.9&#x02009;&#x000b1;&#x02009;0.1<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">2.5&#x02009;&#x000b1;&#x02009;0.02<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">22.9&#x02009;&#x000b1;&#x02009;0.3<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">59.6&#x02009;&#x000b1;&#x02009;0.2<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">46.1&#x02009;&#x000b1;&#x02009;0.3<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">77.5&#x02009;&#x000b1;&#x02009;0.5<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left">8</td><td align="char" char=".">63.2&#x02009;&#x000b1;&#x02009;0.3<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">5.9&#x02009;&#x000b1;&#x02009;0.1<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">1.72&#x02009;&#x000b1;&#x02009;0.03<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">27.7&#x02009;&#x000b1;&#x02009;0.3<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">72.5&#x02009;&#x000b1;&#x02009;0.9<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">54.2&#x02009;&#x000b1;&#x02009;0.4<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">86.3&#x02009;&#x000b1;&#x02009;0.7<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left">16</td><td align="char" char=".">62&#x02009;&#x000b1;&#x02009;0.3<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">5.5&#x02009;&#x000b1;&#x02009;0.1<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">1.99&#x02009;&#x000b1;&#x02009;0.03<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">24.9&#x02009;&#x000b1;&#x02009;0.2<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">68.2&#x02009;&#x000b1;&#x02009;0.6<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td><td align="char" char=".">47.6&#x02009;&#x000b1;&#x02009;0.2 <sup>a,b</sup></td><td align="char" char=".">81.5&#x02009;&#x000b1;&#x02009;0.3<xref rid="TF6" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="TF7" ref-type="table-fn"><sup>b</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="TF5"><p>Each value represents the mean of 6 mice&#x02009;&#x000b1;&#x02009;SEM. Statistical analysis was carried out using one-way analysis of variance (ANOVA) followed by Tukey Kramer multiple comparisons test.</p></fn><fn id="TF6"><label>
<sup>a</sup>
</label><p>significantly different from normal control (NC) (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></fn><fn id="TF7"><label>
<sup>b</sup>
</label><p>significantly different from positive control (PC) (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></fn><fn id="TF8"><label>
<sup>c</sup>
</label><p>significantly different from standard (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="3" id="S0003-S2002-S3003"><title>Oxidative stress markers</title><p>A biomarker for oxidative stress (MDA) was significantly higher in the diabetes group that wasn&#x02019;t treated. Along with this, there was a big drop in plasma antioxidant (GSH). Treatment with gliclazide and hybrids <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> demonstrated a significant reduction of oxidative stress marker (MDA) and significant elevation in GSH as compared to the diabetic non-treated group, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 (<xref rid="t0002" ref-type="table">Table 2</xref>).</p></sec><sec disp-level="3" id="S0003-S2002-S3004"><title>Liver function markers and cholesterol</title><p>The administration of STZ led to the deterioration of liver function biomarkers, as evidenced by a notable increase in AST and ALT levels. In addition to a significant elevation in total cholesterol, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 (<xref rid="t0002" ref-type="table">Table 2</xref>). Treatment of the diabetic group with gliclazide or hybrids <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> for 2&#x02009;weeks resulted in a significant reduction of TC and liver function tests (AST and ALT), <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 (<xref rid="t0002" ref-type="table">Table 2</xref>).</p></sec><sec disp-level="3" id="S0003-S2002-S3005"><title>&#x003b1;-Glucosidase inhibition assay</title><p>The brush border of the small intestine contains the enzyme <italic toggle="yes">&#x003b1;</italic>-glucosidase, which controls the enzymatic hydrolysis of 1,4-linked polysaccharides with glucose as one of the main byproducts. Glucosidase is a target for the treatment of postprandial hyperglycaemia because of the significant role that glucose plays as one of the primary sources of energy in eukaryotes. The anti-diabetic medication acarbose belongs to a group of medications called <italic toggle="yes">&#x003b1;</italic>-glucosidase inhibitors (AGIs), which stop the gastrointestinal tract from absorbing glucose. In vitro <italic toggle="yes">&#x003b1;</italic>-glucosidase inhibitory activity of the target hybrids <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> was assessed in relation to the reference medication acarbose (IC<sub>50</sub>= 0.316&#x02009;&#x000b1;&#x02009;0.02&#x02009;&#x003bc;M). <xref rid="t0003" ref-type="table">Table 3</xref> provided a summary of the findings. Both substances were discovered to be strong inhibitors of the <italic toggle="yes">&#x003b1;</italic>-glucosidase enzyme, as shown below. However, the hydrazone derivative (1&#x02013;(2-(2&#x02013;(7-fluoro-11<italic toggle="yes">H</italic>-indeno[1,2-<italic toggle="yes">b</italic>]quinoxalin-11-ylidene)-hydrazineyl)-4-methyl-thiazol-5-yl)-ethan-1-one) (<bold>8</bold>) was found to be more active as <italic toggle="yes">&#x003b1;</italic>-glucosidase inhibitory activity with IC<sub>50</sub> value of 0.982&#x02009;&#x000b1;&#x02009;0.04&#x02009;&#x000b5;M, followed by Schiff base derivative <bold>6</bold> with IC<sub>50</sub> 2.995&#x02009;&#x000b1;&#x02009;0.09&#x02009;&#x003bc;M. Additionally, the hydrazone derivative <bold>16</bold> has good activity as an inhibitor of <italic toggle="yes">&#x003b1;</italic>-glucosidase, which suggests that the most potent hybrids are those that contain indenoquinoxalene and thiazole connected with hydrazone, followed by Schiff base linker.</p><table-wrap position="float" id="t0003"><label>Table 3.</label><caption><p>Effects of indenoquinoxaline-containing thiazole analogs <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> as well as acarbose on <italic toggle="yes">&#x003b1;</italic>-glucosidase activity.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Ser.</th><th align="center">Cpd. No.</th><th align="center"><italic toggle="yes">&#x003b1;</italic>-Glucosidase IC<sub>50</sub> (&#x000b5;m)</th><th align="center">DF = 100&#x02009;&#x000b1;&#x02009;SD</th></tr></thead><tbody valign="top"><tr><td align="left">1</td><td align="char" char=".">4</td><td align="char" char=".">10.19</td><td align="char" char=".">0.21</td></tr><tr><td align="left">2</td><td align="char" char=".">6</td><td align="char" char=".">2.995</td><td align="char" char=".">0.09</td></tr><tr><td align="left">3</td><td align="char" char=".">8</td><td align="char" char=".">0.982</td><td align="char" char=".">0.04</td></tr><tr><td align="left">4</td><td align="char" char=".">16</td><td align="char" char=".">7.029</td><td align="char" char=".">0.13</td></tr><tr><td align="left">Standard</td><td align="center">Acarbose</td><td align="char" char=".">0.316</td><td align="char" char=".">0.02</td></tr></tbody></table><table-wrap-foot><fn id="TF9"><p>Results represent IC<sub>50</sub> (Half maximal inhibitory concentration) of indenoquinoxaline-containing thiazole analogs&#x02009;&#x000b1;&#x02009;SD as compared to acarbose on <italic toggle="yes">&#x003b1;</italic>-glucosidase activity.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="3" id="S0003-S2002-S3006"><title>&#x003b1;-Amylase inhibition assay</title><p>Changes to <italic toggle="yes">&#x003b1;</italic>-amylase activity have an impact on the utilisation of carbohydrates as a fuel source. This enzyme is necessary for the digestion of complex carbohydrates in humans. Inhibition of <italic toggle="yes">&#x003b1;</italic>-amylase is seen as a possible target for the treatment of diseases like diabetes, obesity, dental caries, and periodontal problems that are linked to carbohydrate intake. <italic toggle="yes">In vitro &#x003b1;</italic>-amylase inhibitory activity of compounds <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> was assessed in relation to the reference medication acarbose (IC<sub>50</sub> = 31.56&#x02009;&#x000b1;&#x02009;1.33&#x02009;&#x003bc;M). <xref rid="t0004" ref-type="table">Table 4</xref> provided a summary of the findings. All the substances examined were discovered to be strong inhibitors of the <italic toggle="yes">&#x003b1;</italic>-amylase enzyme. Particularly, Schiff base derivative <bold>6</bold> and hydrazone derivative <bold>8</bold> show that these moieties are crucial for the anti-diabetic effects.</p><table-wrap position="float" id="t0004"><label>Table 4.</label><caption><p>Effects of indenoquinoxaline-containing thiazole analogs <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> as well as acarbose on <italic toggle="yes">&#x003b1;</italic>-amylase activity.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Ser.</th><th align="center">Cpd. No.</th><th align="center"><italic toggle="yes">&#x003b1;</italic>- Amylase IC<sub>50</sub> (&#x003bc;M)</th><th align="center">DF = 10 &#x000b1;SD</th></tr></thead><tbody valign="top"><tr><td align="left">1</td><td align="char" char=".">4</td><td align="char" char=".">93.36</td><td align="char" char=".">3.95</td></tr><tr><td align="left">2</td><td align="char" char=".">6</td><td align="char" char=".">32.29</td><td align="char" char=".">1.37</td></tr><tr><td align="left">3</td><td align="char" char=".">8</td><td align="char" char=".">17.58</td><td align="char" char=".">0.74</td></tr><tr><td align="left">4</td><td align="char" char=".">16</td><td align="char" char=".">121.6</td><td align="char" char=".">5.14</td></tr><tr><td align="left">Standard</td><td align="center">Acarbose</td><td align="char" char=".">31.56</td><td align="char" char=".">1.33</td></tr></tbody></table><table-wrap-foot><fn id="TF10"><p>Results represent IC<sub>50</sub> (Half maximal inhibitory concentration) of indenoquinoxaline-containing thiazole analogs&#x02009;&#x000b1;&#x02009;SD as compared to acarbose on <italic toggle="yes">&#x003b1;</italic>-amylase activity.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec disp-level="2" id="S0003-S2003"><title>In silico studies</title><sec disp-level="3" id="S0003-S2003-S3001"><title>In silico assessment of physicochemical and ADME properties</title><p>The compounds&#x02019; physicochemical parameters, lipophilicity, water-solubility, pharmacokinetics, drug-likeness, medicinal chemistry properties, and bioavailability score were calculated using SwissADME (<ext-link xlink:href="http://www.swissadme.ch" ext-link-type="uri">http://www.swissadme.ch</ext-link>). Bioavailability is a quick assessment of substances to determine their suitability as an oral medication.</p><p>Using SwissADME, the physicochemical and ADME properties of the newly made thiazole-containing compounds <bold>4</bold>, <bold>5</bold>, <bold>6</bold>, <bold>7</bold>, <bold>8</bold>, <bold>9</bold>, <bold>10</bold>, <bold>12</bold>, <bold>13</bold>, <bold>14</bold>, <bold>15</bold>, <bold>16</bold>, and <bold>17</bold>, as well as <bold>acarbose</bold> and <bold>gliclazide</bold> were studied (<xref rid="t0005" ref-type="table">Table 5</xref>).</p><table-wrap position="float" id="t0005"><label>Table 5.</label><caption><p>Physicochemical properties according to TPSA, and % ABS.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Cpd. No.</th><th align="center">TPSA<xref rid="TF11" ref-type="table-fn"><sup>a</sup></xref></th><th align="center">% ABS<xref rid="TF12" ref-type="table-fn"><sup>b</sup></xref></th></tr></thead><tbody valign="top"><tr><td align="left">4</td><td align="char" char=".">92.87</td><td align="char" char=".">76.96</td></tr><tr><td align="left">5</td><td align="char" char=".">96.34</td><td align="char" char=".">75.76</td></tr><tr><td align="left">6</td><td align="char" char=".">105.57</td><td align="char" char=".">72.58</td></tr><tr><td align="left">7</td><td align="char" char=".">104.9</td><td align="char" char=".">72.81</td></tr><tr><td align="left">8</td><td align="char" char=".">108.37</td><td align="char" char=".">71.61</td></tr><tr><td align="left">9</td><td align="char" char=".">117.6</td><td align="char" char=".">68.43</td></tr><tr><td align="left">10</td><td align="char" char=".">118.56</td><td align="char" char=".">68.1</td></tr><tr><td align="left">12</td><td align="char" char=".">122.72</td><td align="char" char=".">66.66</td></tr><tr><td align="left">13</td><td align="char" char=".">134</td><td align="char" char=".">62.77</td></tr><tr><td align="left">14</td><td align="char" char=".">108.28</td><td align="char" char=".">71.64</td></tr><tr><td align="left">15</td><td align="char" char=".">104.9</td><td align="char" char=".">72.81</td></tr><tr><td align="left">16</td><td align="char" char=".">104.9</td><td align="char" char=".">72.81</td></tr><tr><td align="left">17</td><td align="char" char=".">131.2</td><td align="char" char=".">63.74</td></tr><tr><td align="left">Acarbose</td><td align="char" char=".">321.17</td><td align="char" char=".">&#x02212;1.8</td></tr><tr><td align="left">Gliclazide</td><td align="char" char=".">86.89</td><td align="char" char=".">79.02</td></tr></tbody></table><table-wrap-foot><fn id="TF11"><label>
<sup>a</sup>
</label><p>topological polar surface area (&#x000c5;<sup>2</sup>)</p></fn><fn id="TF12"><label>
<sup>b</sup>
</label><p>% absorption</p></fn></table-wrap-foot></table-wrap><p>Topological polar surface area (TPSA) (<xref rid="t0005" ref-type="table">Table 5</xref>) values for all drugs are less than 140&#x02009;A0, indicating high oral bioavailability. The estimated% ABS shows that all hits ranged between percentages of ABS were computed using the formula % ABS = 109 &#x02013;(0.345 &#x000d7;TPSA).</p><p>Rotatable bonds in all compounds are between 1 and 5, which suggests that the molecule is flexible concerning its bio target. Also, all compounds have hydrogen bond acceptor (HBA) sites less than 10. They also have less than 5 for hydrogen bond donor (HBD) sites. Additionally, Molar refractivity was from 40 to 130 for all compounds except compounds <bold>12</bold> and <bold>13</bold> (<xref rid="t0006" ref-type="table">Table 6</xref>).</p><table-wrap position="float" id="t0006"><label>Table 6.</label><caption><p>Physicochemical properties of the newly synthesised hits.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Cpd. No.</th><th align="center">Fraction Csp3<xref rid="TF13" ref-type="table-fn"><sup>a</sup></xref></th><th align="center">No. of Rotatable bonds</th><th align="center">HBA<xref rid="TF14" ref-type="table-fn"><sup>b</sup></xref></th><th align="center">HBD<xref rid="TF15" ref-type="table-fn"><sup>c</sup></xref></th><th align="center">iLOGP<xref rid="TF16" ref-type="table-fn"><sup>d</sup></xref></th><th align="center">MR<sup>e</sup></th></tr></thead><tbody valign="top"><tr><td align="left">4</td><td align="char" char=".">0.06</td><td align="char" char=".">1</td><td align="char" char=".">6</td><td align="char" char=".">0</td><td align="char" char=".">2.59</td><td align="char" char=".">98.74</td></tr><tr><td align="left">5</td><td align="char" char=".">0.1</td><td align="char" char=".">2</td><td align="char" char=".">6</td><td align="char" char=".">0</td><td align="char" char=".">3.39</td><td align="char" char=".">107.51</td></tr><tr><td align="left">6</td><td align="char" char=".">0.14</td><td align="char" char=".">4</td><td align="char" char=".">7</td><td align="char" char=".">0</td><td align="char" char=".">3.83</td><td align="char" char=".">113.4</td></tr><tr><td align="left">7</td><td align="char" char=".">0.06</td><td align="char" char=".">2</td><td align="char" char=".">6</td><td align="char" char=".">1</td><td align="char" char=".">2.32</td><td align="char" char=".">101.54</td></tr><tr><td align="left">8</td><td align="char" char=".">0.1</td><td align="char" char=".">3</td><td align="char" char=".">6</td><td align="char" char=".">1</td><td align="char" char=".">2.98</td><td align="char" char=".">111.29</td></tr><tr><td align="left">9</td><td align="char" char=".">0.14</td><td align="char" char=".">5</td><td align="char" char=".">7</td><td align="char" char=".">1</td><td align="char" char=".">3.43</td><td align="char" char=".">117.18</td></tr><tr><td align="left">10</td><td align="char" char=".">0</td><td align="char" char=".">1</td><td align="char" char=".">6</td><td align="char" char=".">2</td><td align="char" char=".">2.34</td><td align="char" char=".">100.88</td></tr><tr><td align="left">12</td><td align="char" char=".">0.03</td><td align="char" char=".">5</td><td align="char" char=".">7</td><td align="char" char=".">1</td><td align="char" char=".">4.37</td><td align="char" char=".">178.67</td></tr><tr><td align="left">13</td><td align="char" char=".">0</td><td align="char" char=".">2</td><td align="char" char=".">7</td><td align="char" char=".">2</td><td align="char" char=".">4.37</td><td align="char" char=".">141.48</td></tr><tr><td align="left">14</td><td align="char" char=".">0</td><td align="char" char=".">2</td><td align="char" char=".">4</td><td align="char" char=".">2</td><td align="char" char=".">2.58</td><td align="char" char=".">89.74</td></tr><tr><td align="left">15</td><td align="char" char=".">0.11</td><td align="char" char=".">2</td><td align="char" char=".">6</td><td align="char" char=".">1</td><td align="char" char=".">2.82</td><td align="char" char=".">106.35</td></tr><tr><td align="left">16</td><td align="char" char=".">0.15</td><td align="char" char=".">3</td><td align="char" char=".">6</td><td align="char" char=".">1</td><td align="char" char=".">2.74</td><td align="char" char=".">111.15</td></tr><tr><td align="left">17</td><td align="char" char=".">0.09</td><td align="char" char=".">5</td><td align="char" char=".">8</td><td align="char" char=".">1</td><td align="char" char=".">2.74</td><td align="char" char=".">121.58</td></tr><tr><td align="left">Acarbose</td><td align="char" char=".">0.92</td><td align="char" char=".">9</td><td align="char" char=".">19</td><td align="char" char=".">14</td><td align="char" char=".">0.63</td><td align="char" char=".">136.69</td></tr><tr><td align="left">Gliclazide</td><td align="char" char=".">0.53</td><td align="char" char=".">5</td><td align="char" char=".">4</td><td align="char" char=".">2</td><td align="char" char=".">1.96</td><td align="char" char=".">86.93</td></tr></tbody></table><table-wrap-foot><fn id="TF13"><label>
<sup>a</sup>
</label><p>The ratio of sp<sup>3</sup> hybridised carbons over the total carbon count of the molecule</p></fn><fn id="TF14"><label>
<sup>b</sup>
</label><p>number of hydrogen bond acceptors</p></fn><fn id="TF15"><label>
<sup>c</sup>
</label><p>number of hydrogen bond donors</p></fn><fn id="TF16"><label>
<sup>d</sup>
</label><p>lipophilicity; <sup>e</sup>Molar refractivity.</p></fn></table-wrap-foot></table-wrap><p><xref rid="t0007" ref-type="table">Table 7</xref> for the drug similarity predictor demonstrates that all synthesised compounds meet Lipinski&#x02019;s requirements for oral medications, except for compounds <bold>12</bold> and <bold>13</bold>, which have just one infraction. While occasionally inadequate absorption can result from violating even one of these rules. A common method for assessing a compound&#x02019;s drug-likeness is Lipinski&#x02019;s rule of five. A drug-like compound should meet no more than one of the following requirements, according to Lipinski&#x02019;s rule: &#x02018;a molecular weight of less than 500&#x02009;g/mol, a log <italic toggle="yes">p</italic> values of less than 5, no more than five hydrogen bond donors (HBD), and no more than 10 hydrogen bond acceptor (HBA) sites.&#x02019; Based on the screening method that follows Veber&#x02019;s guidelines, all the hits pass the test for drug resemblance.</p><table-wrap position="float" id="t0007"><label>Table 7.</label><caption><p>Bioavailability and drug-likeness predictions of substances 4&#x02013;17 in addition to Acarbose and Gliclazide.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Cpd. No.</th><th align="center">Lipinski (violations)</th><th align="center">Veber (violations)</th><th align="center">Ghose (violations)</th><th align="center">Egan (violations)</th><th align="center">Muegge (violations)</th><th align="center">Bioavailability Score</th><th align="center">PAINS alerts</th><th align="center">Synthetic Accessibility</th></tr></thead><tbody valign="top"><tr><td align="left">4</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0.55</td><td align="char" char=".">0</td><td align="char" char=".">3.44</td></tr><tr><td align="left">5</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0.55</td><td align="char" char=".">0</td><td align="char" char=".">3.54</td></tr><tr><td align="left">6</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0.55</td><td align="char" char=".">0</td><td align="char" char=".">3.7</td></tr><tr><td align="left">7</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0.55</td><td align="char" char=".">0</td><td align="char" char=".">3.43</td></tr><tr><td align="left">8</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0.55</td><td align="char" char=".">0</td><td align="char" char=".">3.56</td></tr><tr><td align="left">9</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">1</td><td align="char" char=".">0.55</td><td align="char" char=".">0</td><td align="char" char=".">3.75</td></tr><tr><td align="left">10</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0.55</td><td align="char" char=".">1</td><td align="char" char=".">3.66</td></tr><tr><td align="left">12</td><td align="char" char=".">1</td><td align="char" char=".">0</td><td align="char" char=".">3</td><td align="char" char=".">1</td><td align="char" char=".">3</td><td align="char" char=".">0.55</td><td align="char" char=".">1</td><td align="char" char=".">4.78</td></tr><tr><td align="left">13</td><td align="char" char=".">1</td><td align="char" char=".">0</td><td align="char" char=".">3</td><td align="char" char=".">1</td><td align="char" char=".">3</td><td align="char" char=".">0.55</td><td align="char" char=".">1</td><td align="char" char=".">4.78</td></tr><tr><td align="left">14</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0.55</td><td align="char" char=".">0</td><td align="char" char=".">3.03</td></tr><tr><td align="left">15</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0.55</td><td align="char" char=".">0</td><td align="char" char=".">3.99</td></tr><tr><td align="left">16</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0.55</td><td align="char" char=".">0</td><td align="char" char=".">4.09</td></tr><tr><td align="left">17</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0.55</td><td align="char" char=".">0</td><td align="char" char=".">4.09</td></tr><tr><td align="left">Acarbose</td><td align="char" char=".">3</td><td align="char" char=".">1</td><td align="char" char=".">4</td><td align="char" char=".">1</td><td align="char" char=".">5</td><td align="char" char=".">0.17</td><td align="char" char=".">0</td><td align="char" char=".">7.34</td></tr><tr><td align="left">Gliclazide</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0</td><td align="char" char=".">0.55</td><td align="char" char=".">0</td><td align="char" char=".">3.52</td></tr></tbody></table></table-wrap><p>The Ghose, Egan, and Muegge guidelines say that all derivatives except compounds <bold>12</bold> and <bold>13</bold> follow the rule and could be used as medicines. Also, Muegge rules are broken in compound <bold>9</bold>. All compounds that were looked at, had a score of 0.55 for bioavailability which is a high score.</p><p>(PAINS), which was made by SwissADME, showed no alerts for all hits except <bold>10</bold>, <bold>12</bold>, and <bold>13</bold>. Those three only had one alert. Even though PAINS are important features to consider when making drugs to avoid false positives, overestimating them, and using them blindly could mean that promising hits are left out because of fake PAINS. All the analogs were given scores between 3.43 and 4.78 for how easy they are to produce, which means that they can be made in large quantities (<xref rid="t0007" ref-type="table">Table 7</xref>).</p><p>Regarding the pharmacokinetic and medicinal chemistry aspects of the produced compounds (<xref rid="t0008" ref-type="table">Table 8</xref>), it was determined that all derivatives have high gastrointestinal absorption, except compounds <bold>9</bold>, <bold>12</bold>, and <bold>13</bold>. All of them can&#x02019;t get through the blood-brain barrier. This means that these molecules that are targeted to the whole body will have few or no effects on the CNS. The investigation of the P-glycoprotein (P-gp) non-substrate candidature was another key issue throughout the preclinical analysis trial. Pgp functions as an efflux transporter, pumping medicines, other substances, and its substrate out of the cell (<xref rid="F0002" ref-type="fig">Figure 2</xref>).</p><table-wrap position="float" id="t0008"><label>Table 8.</label><caption><p>Pharmacokinetic/ADME properties of the tested novel compounds.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Cpd. No.</th><th align="center">GI absorption</th><th align="center">BBB permeant</th><th align="center">Pgp substrate</th><th align="center">CYP1A2 inhibitor</th><th align="center">CYP2C19 inhibitor</th><th align="center">CYP2C9 inhibitor</th><th align="center">CYP2D6 inhibitor</th><th align="center">CYP3A4 inhibitor</th></tr></thead><tbody valign="top"><tr><td align="left">4</td><td align="left">High</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">No</td><td align="center">Yes</td></tr><tr><td align="left">5</td><td align="left">High</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">No</td><td align="center">Yes</td></tr><tr><td align="left">6</td><td align="left">High</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">No</td><td align="center">Yes</td></tr><tr><td align="left">7</td><td align="left">High</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">No</td><td align="center">Yes</td></tr><tr><td align="left">8</td><td align="left">High</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">No</td><td align="center">Yes</td></tr><tr><td align="left">9</td><td align="left">Low</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">No</td><td align="center">Yes</td></tr><tr><td align="left">10</td><td align="left">High</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td></tr><tr><td align="left">12</td><td align="left">Low</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td></tr><tr><td align="left">13</td><td align="left">Low</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td></tr><tr><td align="left">14</td><td align="left">High</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">No</td><td align="center">Yes</td><td align="center">No</td><td align="center">Yes</td></tr><tr><td align="left">15</td><td align="left">High</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">No</td><td align="center">Yes</td></tr><tr><td align="left">16</td><td align="left">High</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">No</td><td align="center">Yes</td></tr><tr><td align="left">17</td><td align="left">High</td><td align="center">No</td><td align="center">No</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">Yes</td><td align="center">No</td><td align="center">Yes</td></tr><tr><td align="left">Acarbose</td><td align="center">Low</td><td align="center">No</td><td align="center">Yes</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td></tr><tr><td align="left">Gliclazide</td><td align="center">High</td><td align="center">No</td><td align="center">Yes</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">No</td></tr></tbody></table></table-wrap><p>As a result, the hits were examined using the SwissADME website. We discovered that all the hits are not P-gp protein substrates, as shown in (<xref rid="t0008" ref-type="table">Table 8</xref>), implying that these hits have a minimal probability of efflux out of the cell.</p><p>The metabolic profile obtained (<xref rid="t0008" ref-type="table">Table 8</xref>) revealed that all the screened derivatives, except for compounds <bold>9</bold>, <bold>12</bold>, and <bold>13</bold>, are inhibitors of the CYP1A2 enzyme, in addition to acarbose and gliclazide. Except for <bold>10</bold>, <bold>12</bold>, <bold>13</bold>, <bold>14</bold>, <bold>acarbose</bold>, and <bold>gliclazide</bold>, all are also CYP2C19 inhibitors. Compounds <bold>10</bold>, <bold>12</bold>, <bold>13</bold>, <bold>acarbose</bold>, and <bold>gliclazide</bold> are not CYP2C9 inhibitors or substrates. All the hits are not CYP2D6 substrates. All drugs inhibit CYP3A4 except <bold>12</bold>, <bold>13</bold>, <bold>acarbose</bold>, and <bold>gliclazide</bold>.</p></sec><sec disp-level="3" id="S0003-S2003-S3002"><title>Toxicity prediction</title><p>Safety is always crucial to consider while developing a new drug. Safety encompasses a variety of toxicities and unfavourable adverse effects that should be investigated during the drug development journey.</p><p>In this work, we investigate the toxicity of the most promising compounds <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>24</bold> besides two antidiabetic drugs <bold>(acarbose</bold> and <bold>gliclazide)</bold> with the aid of the ProTox-II website (<ext-link xlink:href="https://tox-new.charite.de/protox_II" ext-link-type="uri">https://tox-new.charite.de/protox_II</ext-link>), and pkCSM website (<ext-link xlink:href="http://biosig.unimelb.edu.au/pkcsm/prediction" ext-link-type="uri">http://biosig.unimelb.edu.au/pkcsm/prediction</ext-link>), and the results were shown in <xref rid="t0009 t0010 t0011" ref-type="table">Tables 9, 10, and 11</xref>.</p><table-wrap position="float" id="t0009"><label>Table 9.</label><caption><p>Toxicity of the most promising hits compared to acarbose and gliclazide.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Cpd. No.&#x000a0;</th><th align="center">AMES toxicity</th><th align="center">Max. tolerated dose (human) (log mg/kg/day)</th><th align="center">hERG I inhibitor</th><th align="center">hERG II inhibitor</th><th align="center">Oral Rat Acute Toxicity (LD<sub>50</sub>) (mol/kg)</th><th align="center">Oral Rat Chronic Toxicity (LOAEL) (log mg/kg_bw/day)</th></tr></thead><tbody valign="top"><tr><td align="left">4</td><td align="left">Yes</td><td align="char" char=".">&#x02212;0.409</td><td align="center">No</td><td align="center">No</td><td align="char" char=".">2.682</td><td align="char" char=".">0.862</td></tr><tr><td align="left">6</td><td align="left">No</td><td align="char" char=".">0.187</td><td align="center">No</td><td align="center">Yes</td><td align="char" char=".">2.672</td><td align="char" char=".">0.733</td></tr><tr><td align="left">8</td><td align="left">No</td><td align="char" char=".">0.093</td><td align="center">No</td><td align="center">Yes</td><td align="char" char=".">2.816</td><td align="char" char=".">0.74</td></tr><tr><td align="left">16</td><td align="left">No</td><td align="char" char=".">&#x02212;0.204</td><td align="center">No</td><td align="center">Yes</td><td align="char" char=".">2.505</td><td align="char" char=".">0.745</td></tr><tr><td align="left">Acarbose</td><td align="center">No</td><td align="char" char=".">0.616</td><td align="center">No</td><td align="center">Yes</td><td align="char" char=".">3.176</td><td align="char" char=".">7.01</td></tr><tr><td align="left">Gliclazide</td><td align="center">No</td><td align="char" char=".">&#x02212;0.04</td><td align="center">No</td><td align="center">No</td><td align="char" char=".">1.932</td><td align="char" char=".">1.745</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0010"><label>Table 10.</label><caption><p>Continuation of toxicity of the most promising hits compared to acarbose and gliclazide.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Cpd. No.&#x000a0;</th><th align="center">Hepatotoxicity</th><th align="center">Skin Sensitisation</th><th align="center"><italic toggle="yes">T.Pyriformis</italic> toxicity (log ug/L)</th><th align="center">Minnow toxicity (log mM)</th></tr></thead><tbody valign="top"><tr><td align="left">4</td><td align="left">Yes</td><td align="center">No</td><td align="char" char=".">0.413</td><td align="char" char=".">0.321</td></tr><tr><td align="left">6</td><td align="left">Yes</td><td align="center">No</td><td align="char" char=".">0.287</td><td align="char" char=".">0.729</td></tr><tr><td align="left">8</td><td align="left">Yes</td><td align="center">No</td><td align="char" char=".">0.294</td><td align="char" char=".">0.605</td></tr><tr><td align="left">16</td><td align="left">Yes</td><td align="center">No</td><td align="char" char=".">0.385</td><td align="char" char=".">&#x02212;0.905</td></tr><tr><td align="left">Acarbose</td><td align="center">No</td><td align="center">No</td><td align="char" char=".">0.285</td><td align="char" char=".">15.114</td></tr><tr><td align="left">Gliclazide</td><td align="center">Yes</td><td align="center">No</td><td align="char" char=".">1.038</td><td align="char" char=".">0.659</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0011"><label>Table 11.</label><caption><p>Toxicity prediction with ProTox-II website for the most active derivatives compared to acarbose and gliclazide.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Cpd. No.&#x000a0;</th><th align="center">LD<sub>50</sub> (mg/kg)</th><th align="center">Toxicity Class</th><th align="center">Carcinogenicity Prediction (Probability)</th><th align="center">Immunotoxicity Prediction (Probability)</th><th align="center">Mutagenicity Prediction (Probability)</th><th align="center">Cytotoxicity Prediction (Probability)</th></tr></thead><tbody valign="top"><tr><td align="left">4</td><td align="char" char=".">2000</td><td align="char" char=".">4</td><td align="center">Inactive (0.54)</td><td align="left">Inactive (0.94)</td><td align="left">Inactive (0.58)</td><td align="center">Inactive (0.72)</td></tr><tr><td align="left">6</td><td align="char" char=".">300</td><td align="char" char=".">3</td><td align="center">Inactive (0.51)</td><td align="left">Inactive (0.97)</td><td align="left">Inactive (0.68)</td><td align="center">Inactive (0.68)</td></tr><tr><td align="left">8</td><td align="char" char=".">807</td><td align="char" char=".">4</td><td align="center">Inactive (0.53)</td><td align="left">Inactive (0.96)</td><td align="left">Active (0.58)</td><td align="center">Inactive (0.75)</td></tr><tr><td align="left">16</td><td align="char" char=".">2000</td><td align="char" char=".">4</td><td align="center">Active (0.5)</td><td align="left">Active (0.59)</td><td align="left">Active (0.52)</td><td align="center">Inactive (0.77)</td></tr><tr><td align="left">Acarbose</td><td align="char" char=".">24000</td><td align="char" char=".">6</td><td align="center">Inactive (0.84)</td><td align="left">Active (0.99)</td><td align="left">Inactive (0.76)</td><td align="center">Inactive (0.70)</td></tr><tr><td align="left">Gliclazide</td><td align="char" char=".">1750</td><td align="char" char=".">4</td><td align="center">Inactive (0.79)</td><td align="left">Inactive (0.99)</td><td align="left">Inactive (0.79)</td><td align="center">Inactive (0.66)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0012"><label>Table 12.</label><caption><p>Binding energies S (Kcal mol<sup>&#x02212;1</sup>), receptor interactions and distances in angstroms of acarbose, with <italic toggle="yes">&#x003b1;</italic>-amylase (PDB ID: 1B2Y) and <italic toggle="yes">&#x003b1;</italic>-glucosidase (PDB ID: 5NN8) (London dG as a scoring function).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Ligand/ Protein</th><th align="center">Receptor Amino Acid names and number</th><th align="center">Type of interaction</th><th align="center">Distance (&#x000c5;)</th></tr></thead><tbody valign="top"><tr><td align="left"><italic toggle="yes">&#x003b1;</italic>-Amylase</td><td align="center">GLU 240</td><td align="center">H-donor</td><td align="char" char=".">2.78</td></tr><tr><td align="left">&#x000a0;</td><td align="center">HIS 201</td><td align="center">H-donor</td><td align="char" char=".">2.67</td></tr><tr><td align="left">&#x000a0;</td><td align="center">GLU 233</td><td align="center">H-donor</td><td align="char" char=".">2.58</td></tr><tr><td align="left">&#x000a0;</td><td align="center">GLU 233</td><td align="center">H-donor</td><td align="char" char=".">2.63</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ASP 300</td><td align="center">H-donor</td><td align="char" char=".">3.03</td></tr><tr><td align="left">&#x000a0;</td><td align="center">GLU 233</td><td align="center">H-donor</td><td align="char" char=".">3.26</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ASP 300</td><td align="center">H-donor</td><td align="char" char=".">2.54</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ASP 197</td><td align="center">H-donor</td><td align="char" char=".">3.37</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ASP 197</td><td align="center">H-donor</td><td align="char" char=".">2.7</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ASP 300</td><td align="center">H-donor</td><td align="char" char=".">3.18</td></tr><tr><td align="left">&#x000a0;</td><td align="center">TRP 59</td><td align="center">H-donor</td><td align="char" char=".">2.69</td></tr><tr><td align="left">&#x000a0;</td><td align="center">THR 163</td><td align="center">H-donor</td><td align="char" char=".">2.8</td></tr><tr><td align="left">&#x000a0;</td><td align="center">LYS 200</td><td align="center">H-acceptor</td><td align="char" char=".">2.77</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ARG 195</td><td align="center">H-acceptor</td><td align="char" char=".">2.91</td></tr><tr><td align="left">&#x000a0;</td><td align="center">HIS 299</td><td align="center">H-acceptor</td><td align="char" char=".">3.06</td></tr><tr><td align="left">&#x000a0;</td><td align="center">HIS 299</td><td align="center">H-acceptor</td><td align="char" char=".">3.37</td></tr><tr><td align="left">&#x000a0;</td><td align="center">HIS 305</td><td align="center">H-acceptor</td><td align="char" char=".">2.76</td></tr><tr><td align="left">&#x000a0;</td><td align="center">GLN 63</td><td align="center">H-acceptor</td><td align="char" char=".">2.86</td></tr><tr><td align="left">&#x000a0;</td><td align="center">TYR 151</td><td align="center">H-pi</td><td align="char" char=".">4.59</td></tr><tr><td align="left">&#x000a0;</td><td align="center">TRP 59</td><td align="center">H-pi</td><td align="char" char=".">4.47</td></tr><tr><td align="left">&#x000a0;</td><td align="center">TRP 59</td><td align="center">H-pi</td><td align="char" char=".">3.92</td></tr><tr><td align="left"><italic toggle="yes">&#x003b1;</italic>-Glucosidase</td><td align="center">ASP 282</td><td align="center">H-donor</td><td align="char" char=".">2.77</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ASP 282</td><td align="center">H-donor</td><td align="char" char=".">2.65</td></tr><tr><td align="left">&#x000a0;</td><td align="center">MET 519</td><td align="center">H-donor</td><td align="char" char=".">3.18</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ASP 616</td><td align="center">H-donor</td><td align="char" char=".">3.24</td></tr><tr><td align="left">&#x000a0;</td><td align="center">MET 519</td><td align="center">H-donor</td><td align="char" char=".">4.32</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ASP 616</td><td align="center">H-donor</td><td align="char" char=".">2.55</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ASP 404</td><td align="center">H-donor</td><td align="char" char=".">2.65</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ASP 404</td><td align="center">H-donor</td><td align="char" char=".">2.54</td></tr><tr><td align="left">&#x000a0;</td><td align="center">ARG 600</td><td align="center">H-acceptor</td><td align="char" char=".">2.64</td></tr><tr><td align="left">&#x000a0;</td><td align="center">HIS 674</td><td align="center">H-acceptor</td><td align="char" char=".">2.87</td></tr><tr><td align="left">&#x000a0;</td><td align="center">PHE 649</td><td align="center">H-pi</td><td align="char" char=".">4.28</td></tr></tbody></table></table-wrap><p>Except for compound <bold>4</bold>, none of the compounds in <xref rid="t0009" ref-type="table">Table 9</xref> including <bold>acarbose</bold> and <bold>gliclazide</bold> exhibited AMES toxicity in the pkCSM web tools. The maximum acceptable human dose for the components that are the most bioactive ranges from &#x02212;0.409 to 0.616 log mg/kg/day. Additionally, it was discovered that none of the tested substances inhibit hERG I, which is a positive finding that makes the substances safer and lowers the risk factors for torsade de pointes (a deadly arrhythmia). Contrarily, the only compounds that do not block hERG II are compound <bold>4</bold> and gliclazide. Gliclazide&#x02019;s acute oral rat toxicity values ranged from 1.932&#x02009;mol/kg to 3.176&#x02009;mol/kg, whereas acarbose&#x02019;s acute oral rat toxicity (LOAEL) values ranged from 0.737 to 7.01 log mg/kg_ bw/day.</p><p>Hepatotoxicity is a rare reason for drug development to halt during the preclinical stage. In fact, liver toxicity is typically reversible in contrast to other organ toxicity, and sensitive serum enzyme assays can be used to monitor liver toxicity in humans. To confirm whether a substance is also hepatotoxic in humans, it is frequently tested on humans after it was discovered to be hepatotoxic in an animal species. In our investigation, gliclazide and all other evaluated substances are anticipated to be hepatotoxic. Hepatotoxicity was absent in just acarbose. However, none of the hits revealed any signs of cutaneous sensitivity. <italic toggle="yes">Tetrahymena pyriformis&#x02019;s</italic> toxicity ranges from 0.285 to 1.038, making it a common indicator of toxicity endpoints.</p><p>As shown in (<xref rid="t0011" ref-type="table">Table 11</xref>), the toxicity profile for the active chemicals <bold>4</bold>, <bold>6</bold>, and <bold>gliclazide</bold> demonstrated that they were not mutagenic, immune-toxic, carcinogenic, or cytotoxic, with LD<sub>50</sub> values of 2000, 300, and 1750, respectively. Compound <bold>8</bold> was projected to be non-carcinogenic, non-immunogenic, and non-cytotoxic but active for mutagenicity, with an LD<sub>50</sub> of 807&#x02009;mg/kg. Furthermore, compound <bold>16</bold> was noncytotoxic, but it was mutagenic, immune-toxic, and carcinogenic in toxicity experiments, with an LD<sub>50</sub> of 2000&#x02009;mg/kg. Acarbose was also discovered to be immunogenic but not carcinogenic, mutagenic, or cytotoxic. Furthermore, the novel-generated quinoxaline derivatives <bold>4</bold>, <bold>8</bold>, and <bold>16</bold> were classified as class four toxicity, whereas derivative <bold>6</bold> was classified as class three toxicity.</p></sec><sec disp-level="3" id="S0003-S2003-S3003"><title>Docking studies</title><p>To verify the accuracy of the docking procedure used in this docking investigation, self-docking of the co-crystalized ligand (acarbose) in the binding site was performed for <italic toggle="yes">&#x003b1;</italic>-amylase and &#x003b1;-glucosidase. The low RMSD between acarbose&#x02019;s re-docked stance and native pose served as proof that the validation stage was successful. The RMSD for self-docking of <italic toggle="yes">&#x003b1;</italic>-amylase (PDB ID: 1B2Y) was 0.6608&#x02009;&#x000c5;. The RMSD value for self-docking of <italic toggle="yes">&#x003b1;</italic>-glucosidase (PDB ID: 5NN8) was 0.5693&#x02009;&#x000c5;. Additionally, as shown in <xref rid="F0003" ref-type="fig">Figure 3</xref>, the re-docked acarbose pose in both proteins demonstrated the capacity to overlap the native ligand posture and occupy important contacts made possible by the co-crystallized ligand with the active site hot spots in <italic toggle="yes">&#x003b1;</italic>-amylase and <italic toggle="yes">&#x003b1;</italic>-glucosidase (<xref rid="t0012" ref-type="table">Table 12</xref>).</p><fig position="float" id="F0002"><label>Figure 2.</label><caption><p>Diagrams showing how compounds <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> correlate to drugs. The coloured area is a good physical and chemical space for oral bioavailability. LIPO (lipophilicity); SIZE (molecular weight); POLAR (polarity); INSOLU (insolubility); INSATU (insaturation); FLEX (flexibility).</p></caption><graphic xlink:href="IENZ_A_2367128_F0002_C" content-type="color" position="float"/></fig><p>Compounds <bold>6</bold> and <bold>8</bold> showed the lowest energy in the case of <italic toggle="yes">&#x003b1;-</italic>amylase, with score values of &#x02212;9.72 and &#x02212;11.59&#x02009;kCal/mol, respectively. This demonstrates that it agrees with the findings of the enzyme assay. Compound <bold>8</bold> was discovered to function as an H-bond acceptor from amino acid <bold>Lys200</bold> as well as an H-bond donor to <bold>Glu233</bold>. The interaction between compound <bold>8</bold> and <bold>His101</bold> was shown to be H-arene. Compound <bold>6</bold> displayed three H-bonds with the binding pocket, as well as three arene-H interactions with <bold>His305</bold> and <bold>Gly306</bold>. <xref rid="t0013" ref-type="table">Table 13</xref> provides a summary of ligand interactions. Compound <bold>16</bold> revealed two H-arene contacts with <bold>Trp59</bold>, one H-bond with <bold>Gln63</bold>, and two arene-H interactions with <bold>Leu162</bold>. Compound <bold>4</bold> had just one arene-H interaction with <bold>Gly306</bold>, and it had the greatest energy score of &#x02212;7.93&#x02009;kCal/mol. <xref rid="F0004" ref-type="fig">Figure 4</xref> shows ligand interactions and binding modalities.</p><fig position="float" id="F0003"><label>Figure 3.</label><caption><p>A) Overlay between co-crystallized ligand (yellow) and re-docked pose (green) of acarbose (RMSD= 0.66&#x02009;&#x000c5;) in <italic toggle="yes">&#x003b1;</italic>-amylase (PDB ID: 1B2Y), complex overlay and ligand interactions. B) Overlay between co-crystallized ligand (yellow) and re-docked pose (green) of acarbose (RMSD= 0.56&#x02009;&#x000c5;) in <italic toggle="yes">&#x003b1;</italic>-glucosidase (PDB ID: 5NN8), complex overlay and ligand interactions.</p></caption><graphic xlink:href="IENZ_A_2367128_F0003_C" content-type="color" position="float"/></fig><table-wrap position="float" id="t0013"><label>Table 13.</label><caption><p>Binding energies S (Kcal mol<sup>&#x02212;1</sup>), receptor interactions, and distances in angstroms of compounds <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold>, with <italic toggle="yes">&#x003b1;</italic>-amylase (PDB ID: 1B2Y) and <italic toggle="yes">&#x003b1;</italic>-glucosidase (PDB ID: 5NN8) (London dG as a scoring function).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Compound</th><th align="center">Binding Energy (<italic toggle="yes">S</italic>) (kCal/mol)</th><th align="center">Receptor Amino Acid</th><th align="center">Type of interaction</th><th align="center">Distance (&#x000c5;)</th><th align="center">Binding Energy (<italic toggle="yes">S</italic>) (kCal/mol)</th><th align="center">Receptor Amino Acid</th><th align="center">Type of interaction</th><th align="center">Distance (&#x000c5;)</th></tr><tr><th colspan="4" align="center">1B2Y</th><th colspan="4" align="center">5NN8</th></tr></thead><tbody valign="top"><tr><td align="left">4</td><td align="char" char=".">&#x02212;7.93</td><td align="center">GLY 306</td><td align="center">pi-H</td><td align="char" char=".">3.81</td><td align="char" char=".">&#x02212;7.83</td><td align="center">HIS 674</td><td align="center">H-acceptor</td><td align="char" char=".">3.38</td></tr><tr><td align="left">6</td><td align="char" char=".">&#x02212;9.72</td><td align="center">HIS 201</td><td align="center">H-donor</td><td align="char" char=".">3.6</td><td align="char" char=".">&#x02212;10.63</td><td align="center">ASP 616</td><td align="center">H-donor</td><td align="char" char=".">3.53</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">HIS 305</td><td align="center">H-acceptor</td><td align="char" char=".">3</td><td align="left">&#x000a0;</td><td align="center">ASP 645</td><td align="center">H-donor</td><td align="char" char=".">3.15</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">LYS 200</td><td align="center">H-acceptor</td><td align="char" char=".">2.85</td><td align="left">&#x000a0;</td><td align="center">TRP 481</td><td align="center">H-acceptor</td><td align="char" char=".">3.2</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">HIS 305</td><td align="center">pi-H</td><td align="char" char=".">4.49</td><td align="left">&#x000a0;</td><td align="center">HIS 674</td><td align="center">H-acceptor</td><td align="char" char=".">3.38</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">GLY 306</td><td align="center">pi-H</td><td align="char" char=".">4.01</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">GLY 306</td><td align="center">pi-H</td><td align="char" char=".">4.61</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">8</td><td align="char" char=".">&#x02212;11.59</td><td align="center">GLU 233</td><td align="center">H-donor</td><td align="char" char=".">3.3</td><td align="char" char=".">&#x02212;10.79</td><td align="center">ASP 616</td><td align="center">H-donor</td><td align="char" char=".">3.39</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">LYS 200</td><td align="center">H-acceptor</td><td align="char" char=".">2.9</td><td align="left">&#x000a0;</td><td align="center">ASP 616</td><td align="center">H-donor</td><td align="char" char=".">3.22</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">HIS 101</td><td align="center">H-pi</td><td align="char" char=".">4.84</td><td align="left">&#x000a0;</td><td align="center">TRP 481</td><td align="center">H-acceptor</td><td align="char" char=".">3.25</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">HIS 674</td><td align="center">H-acceptor</td><td align="char" char=".">2.95</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">LEU 283</td><td align="center">pi-H</td><td align="char" char=".">4.57</td></tr><tr><td align="left">16</td><td align="char" char=".">&#x02212;7.37</td><td align="center">GLN 63</td><td align="center">H-acceptor</td><td align="char" char=".">3.39</td><td align="char" char=".">&#x02212;9.37</td><td align="center">ASP 616</td><td align="center">H-donor</td><td align="char" char=".">3.37</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">TRP 59</td><td align="center">H-pi</td><td align="char" char=".">4.34</td><td align="left">&#x000a0;</td><td align="center">ASP 616</td><td align="center">H-donor</td><td align="char" char=".">3.44</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">TRP 59</td><td align="center">H-pi</td><td align="char" char=".">3.88</td><td align="left">&#x000a0;</td><td align="center">TRP 481</td><td align="center">H-acceptor</td><td align="char" char=".">3.18</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">LEU 162</td><td align="center">pi-H</td><td align="char" char=".">4.02</td><td align="left">&#x000a0;</td><td align="center">LEU 83</td><td align="center">pi-H</td><td align="char" char=".">4.6</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">LEU 162</td><td align="center">pi-H</td><td align="char" char=".">4.23</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td></tr></tbody></table></table-wrap><p>Moreover, compounds <bold>6</bold> and <bold>8</bold> showed the lowest energy in the case of <italic toggle="yes">&#x003b1;</italic>-glucosidase, with score values of &#x02212;10.63 and &#x02212;10.79&#x02009;kCal/mol, respectively. This demonstrates that it agrees with the findings of the enzyme assay. Compound <bold>6</bold> was discovered to function as an H-bond acceptor from the amino acids <bold>Trp481</bold> and <bold>His674</bold> as well as an H-bond donor to the amino acids <bold>Asp616</bold> and <bold>Asp645</bold>. Compound <bold>8</bold> revealed the same ligand interactions with the same amino acids as compound <bold>6</bold> (shown in <xref rid="F0005" ref-type="fig">Figure 5</xref>), in addition to a comparable manner of contact. However, compound <bold>8</bold> demonstrated an additional arene-H interaction with <bold>Leu283</bold>. <xref rid="t0013" ref-type="table">Table 13</xref> provides a summary of ligand interactions. Compound <bold>16</bold> had a score of &#x02212;9.37&#x02009;kCal/mol, which was slightly higher than average in terms of energy. It displayed three contacts with <bold>Asp616</bold>, <bold>Asp645</bold>, and <bold>Trp481</bold> as well as an additional arene-H interaction with <bold>Leu83</bold>, which were shared by compounds <bold>6</bold> and <bold>8</bold> as well. With just one H-bond to <bold>His674</bold>, compound <bold>4</bold> has the highest energy score, measuring &#x02212;7.83&#x02009;kCal/mol.</p><fig-group position="float" id="F0004"><label>Figure 4.</label><caption><p>3D binding modes &#x00026; 2D ligand interactions with <italic toggle="yes">&#x003b1;</italic>-amylase (PDB ID: 1B2Y) of the most active compounds, (A) Compound <bold>4</bold>, (B) Compound <bold>6</bold>, (C) Compound <bold>8</bold>, (D) Compound <bold>16</bold>.</p></caption><fig position="anchor" id="F0004a"><graphic xlink:href="IENZ_A_2367128_F0004a_C" content-type="color" position="float"/></fig><fig position="anchor" id="F0004b"><graphic xlink:href="IENZ_A_2367128_F0004b_C" content-type="color" position="float"/></fig></fig-group><fig-group position="float" id="F0005"><label>Figure 5.</label><caption><p>3D binding modes &#x00026; 2D ligand interactions with <italic toggle="yes">&#x003b1;</italic>-glucosidase (PDB ID: 5NN8) of the most active compounds, (A) Compound 4, (B) Compound 6, (C) Compound 8, (D) Compound 16.</p></caption><fig position="anchor" id="F0005a"><graphic xlink:href="IENZ_A_2367128_F0005a_C" content-type="color" position="float"/></fig><fig position="anchor" id="F0005b"><graphic xlink:href="IENZ_A_2367128_F0005b_C" content-type="color" position="float"/></fig></fig-group></sec></sec></sec><sec sec-type="conclusions" disp-level="1" id="S0004"><title>Conclusion</title><p>A series of novel indenoquinoxaline, Schiff&#x02019;s base derivatives <bold>4&#x02013;6</bold>, hydrazone derivatives <bold>7&#x02013;9</bold>, arylidine-indenoquinoxaline derivatives <bold>10</bold>, <bold>12</bold>, and <bold>13</bold>, and thiazole derivatives <bold>15&#x02013;17</bold> was designed, synthesised, and subjected to biological evaluation as antidiabetic agents. The results indicated that there are four hybrids with good activity. Compounds <bold>4</bold>, <bold>6</bold>, <bold>8</bold>, and <bold>16</bold> possess promising antidiabetic properties demonstrated by decreasing glucose level, increasing insulin level, also causes inhibition of <italic toggle="yes">&#x003b1;</italic>-amylase and <italic toggle="yes">&#x003b1;</italic>-glucosidase activities. In addition to their antioxidant, hypocholesteremic, renoprotective and hepatoprotective properties. When compared to acarbose, a reference medication (IC<sub>50</sub>=0.316&#x02009;&#x000b1;&#x02009;0.02 and 31.56&#x02009;&#x000b1;&#x02009;1.33&#x02009;&#x003bc;M), the four compounds showed moderate to powerful activity with IC<sub>50</sub> values of 0.982&#x02009;&#x000b1;&#x02009;0.04, 10.19&#x02009;&#x000b1;&#x02009;0.21, 17.58&#x02009;&#x000b1;&#x02009;0.74, and 121.6&#x02009;&#x000b1;&#x02009;5.14&#x02009;&#x003bc;M, respectively. The Schiff base derivative <bold>6</bold> and the hydrazone derivative <bold>8</bold> demonstrate the importance of these moieties for the anti-diabetic actions as these derivatives show the best result when compared to the standard acarbose as <italic toggle="yes">&#x003b1;</italic>-amylase &#x00026; <italic toggle="yes">&#x003b1;</italic>-glucosidase inhibitors. In addition, docking experiments were used to confirm the binding interactions, and all hybrid and standard medicines underwent in silico ADME and toxicity tests. Future work will be done for the most promising hybrids <bold>6</bold> and <bold>8</bold>, to study another mode of actions as well as formulation in different dosage form to be tested.</p></sec><sec disp-level="1" id="S0005"><title>Ethical approval</title><p>The least number of animals necessary to attain statistical significance was used. Mice were housed under a 12-hour light/dark cycle; a relative humidity of 50%; and a controlled temperature of 22&#x02009;&#x000b1;&#x02009;1 &#x000b0;C; with free access to food and water. At the end of the experiment, mice were euthanatized by cervical dislocation. The protocol of the current research study is in line with the ARRIVE guidelines for the use and care of laboratory animals and approved by the research ethics committee for experimental and clinical studies at the Faculty of Pharmacy (Girls), Al-Azhar University (Permit number: ES 408, 1/6/2023).</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM7415" position="float" content-type="local-data"><caption><title>Supplemental Material</title></caption><media xlink:href="IENZ_A_2367128_SM7415.pdf"/></supplementary-material></sec></body><back><sec disp-level="1" id="S0006"><title>Authors&#x02019; contributions</title><p>Conceptualisation, E.A.F., A.R., Y.A.A., A.M.M., and M.S.A.; Data curation, N.A.G., E.A.F., A.R., O.A.A.A., Y.A.A., A.M. M., and M.S.A.; Formal analysis, N.A.G., E.A.F., A.R., O.A.A.A., A.M. M., and M.S.A.; Investigation, N.A.G., E.A.F., A.R., O.A.A.A., Y.A.A. and M.S.A.; Methodology, N.A.G., E.A.F., A.R., A.M.M., and M.S.A.; Project administration, Y.A.A., and E.A.F.; Resources, E.A.F., O.A.A.A.; Software, E.A.F.; Supervision, E.A.F., Y.A.A.; Validation, E.A.F., and A.M.M.; Writing&#x02014;original draft, E.A.F., N.A.G., A.R., A.M. M., and M.S.A.; Writing&#x02014;review &#x00026; editing, E.A.F., N.A.G., A.R. and M.S.A. All authors have read and agreed to the published version of the manuscript.</p></sec><sec disp-level="1" id="S0007"><title>Institutional review board statement</title><p>Not applicable.</p></sec><sec disp-level="1" id="S0008"><title>Informed consent statement</title><p>Not applicable.</p></sec><sec sec-type="COI-statement" disp-level="1" id="S0022"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec sec-type="data-availability" disp-level="1" id="S0009"><title>Data availability statement</title><p>Data is contained within the article and <ext-link xlink:href="10.1080/14756366.2024.2367128" ext-link-type="doi">supplementary material</ext-link>.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <article-title>Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a who consultation. Part 1, diagnosis and classification of diabetes mellitus. In. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a who consultation</article-title>. <source>Part 1, Diagnosis and Classification of Diabetes Mellitus: World Health Organization</source>. <year>1999</year>;<volume>25</volume>:<fpage>1</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adaikalakoteswari</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Balasubramanyam</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mohan</surname>
<given-names>V.</given-names></string-name></person-group>
<article-title>Telomere shortening occurs in Asian Indian type 2 diabetic patients</article-title>. <source>Diabetic Med</source>. <year>2005</year>;<volume>22</volume>(<issue>9</issue>):<fpage>1151</fpage>&#x02013;<lpage>1156</lpage>.<pub-id pub-id-type="pmid">16108841</pub-id>
</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miles</surname>
<given-names>PD</given-names></string-name>, <string-name><surname>Levisetti</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Reichart</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Khoursheed</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Moossa</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Olefsky</surname>
<given-names>JM.</given-names></string-name></person-group>
<article-title>Kinetics of insulin action in vivo: identification of rate-limiting steps</article-title>. <source>Diabetes</source>. <year>1995</year>;<volume>44</volume>(<issue>8</issue>):<fpage>947</fpage>&#x02013;<lpage>953</lpage>.<pub-id pub-id-type="pmid">7622001</pub-id>
</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zou</surname>
<given-names>M-H.</given-names></string-name></person-group>
<article-title>Molecular insights and therapeutic targets for diabetic endothelial dysfunction</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>(<issue>13</issue>):<fpage>1266</fpage>&#x02013;<lpage>1286</lpage>.<pub-id pub-id-type="pmid">19786641</pub-id>
</mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mahfoz</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Hassanein</surname>
<given-names>NM</given-names></string-name>, <string-name><surname>Shoka</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>El-Latif</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hekma</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Diabetic nephropathy: Review of novel experimental and clinical strategies</article-title>. <source>Bull Fac Pharm Cairo Univ</source>. <year>2019</year>;<volume>57</volume>(<issue>2</issue>):<fpage>127</fpage>&#x02013;<lpage>136</lpage>.</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>El Maleky</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Mahfoz</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Osman</surname>
<given-names>AO</given-names></string-name>, <string-name><surname>Abd El-Latif</surname>
<given-names>HA.</given-names></string-name></person-group>
<article-title>Investigation of the impacts of zamzam water on streptozotocin-induced diabetic nephropathy in rats. in-vivo and in-vitro study</article-title>. <source>Biomed Pharmacother</source> . <year>2021</year>;<volume>138</volume>:<fpage>111474</fpage>.<pub-id pub-id-type="pmid">33773466</pub-id>
</mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mehmood</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Mughal</surname>
<given-names>EU</given-names></string-name>, <string-name><surname>Elkaeed</surname>
<given-names>EB</given-names></string-name>, <string-name><surname>Obaid</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Nazir</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Al-Ghulikah</surname>
<given-names>HA</given-names></string-name>, <string-name><surname>Naeem</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Al-Rooqi</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Ahmed</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Shah</surname>
<given-names>SWA</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of novel 2, 3-dihydro-1, 5-benzothiazepines as &#x003b1;-glucosidase inhibitors: In vitro, in vivo, kinetic, sar, molecular docking, and qsar studies</article-title>. <source>ACS Omega</source>. <year>2022</year>;<volume>7</volume>(<issue>34</issue>):<fpage>30215</fpage>&#x02013;<lpage>30232</lpage>.<pub-id pub-id-type="pmid">36061741</pub-id>
</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jarald</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Joshi</surname>
<given-names>SB</given-names></string-name>, <string-name><surname>Jain</surname>
<given-names>DC.</given-names></string-name></person-group>
<source>Diabetes and Herbal Medicines</source>. IJPT. <year>2008</year>;7(1):<fpage>97</fpage>&#x02013;<lpage>106</lpage>.</mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Henrissat</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Bairoch</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>New families in the classification of glycosyl hydrolases based on amino acid sequence similarities</article-title>. <source>Biochem J</source>. <year>1993</year>;<volume>293 (Pt 3)</volume> (<issue>Pt 3</issue>):<fpage>781</fpage>&#x02013;<lpage>788</lpage>.<pub-id pub-id-type="pmid">8352747</pub-id>
</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dauw</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Simeon</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Alruwaily</surname>
<given-names>AF</given-names></string-name>, <string-name><surname>Sanguedolce</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Hollingsworth</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Roberts</surname>
<given-names>WW</given-names></string-name>, <string-name><surname>Faerber</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>JS</given-names>, <suffix>Jr</suffix></string-name>, <string-name><surname>Ghani</surname>
<given-names>KR.</given-names></string-name></person-group>
<article-title>Contemporary practice patterns of flexible ureteroscopy for treating renal stones: Results of a worldwide survey</article-title>. <source>J Endourol</source>. <year>2015</year>;<volume>29</volume>(<issue>11</issue>):<fpage>1221</fpage>&#x02013;<lpage>1230</lpage>.<pub-id pub-id-type="pmid">26154856</pub-id>
</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Sales</surname>
<given-names>PMD</given-names></string-name>, <string-name><surname>PMd</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Simeoni</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>PdOMD</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Silveira</surname>
<given-names>D.</given-names></string-name></person-group>
<article-title>&#x00391;-amylase inhibitors: a review of raw material and isolated compounds from plant source. J Pharm Pharm Sci. 2012;15(1):141&#x02013;183. </article-title></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><article-title>Nair SS, Kavrekar V, Mishra A. In vitro studies on alpha amylase and alpha glucosidase inhibitory activities of selected plant extracts. Eur</article-title>
<source>J Exp Biol</source>. <year>2013</year>;<volume>3</volume>(<issue>1</issue>):<fpage>128</fpage>&#x02013;<lpage>132</lpage>.</mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sundarram</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Murthy</surname>
<given-names>TPK.</given-names></string-name></person-group>
<article-title>&#x00391;-amylase production and applications: a review</article-title>. <source>J Appl Environ Microbiol</source>. <year>2014</year>;2(<issue>4</issue>):<fpage>166</fpage>&#x02013;<lpage>175</lpage>.</mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Taha</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Javid</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Imran</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Selvaraj</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Chigurupati</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ullah</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Rahim</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Khan</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Mohammad</surname>
<given-names>JI</given-names></string-name>, <string-name><surname>Khan</surname>
<given-names>KM.</given-names></string-name></person-group>
<article-title>Synthesis and study of the &#x003b1;-amylase inhibitory potential of thiadiazole quinoline derivatives</article-title>. <source>Bioorg Chem</source>. <year>2017</year>;<volume>74</volume>(:<fpage>179</fpage>&#x02013;<lpage>186</lpage>.<pub-id pub-id-type="pmid">28826047</pub-id>
</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petrou</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Fesatidou</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Geronikaki</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Thiazole ring&#x02014;a biologically active scaffold</article-title>. <source>Molecules</source>. <year>2021</year>; <volume>26</volume>(<issue>11</issue>):<fpage>3166</fpage>.<pub-id pub-id-type="pmid">34070661</pub-id>
</mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xie</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Peng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Deng</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>W.</given-names></string-name></person-group>
<article-title>Synthesis, biological evaluation, and molecular docking studies of novel isatin-thiazole derivatives as &#x003b1;-glucosidase inhibitors</article-title>. <source>Molecules</source>. <year>2017</year>;<volume>22</volume>(<issue>4</issue>):<fpage>659</fpage>.<pub-id pub-id-type="pmid">28425975</pub-id>
</mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>G</given-names></string-name>, <string-name><surname>He</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Peng</surname>
<given-names>Z.</given-names></string-name></person-group>
<article-title>Design, synthesis and biological evaluation of novel coumarin thiazole derivatives as &#x003b1;-glucosidase inhibitors</article-title>. <source>Bioorg Chem</source>. <year>2016</year>;<volume>65</volume>(:<fpage>167</fpage>&#x02013;<lpage>174</lpage>.<pub-id pub-id-type="pmid">26964016</pub-id>
</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghani</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Albarrag</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yurtta&#x0015f;</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Demirci</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Kaplancikli</surname>
<given-names>ZA.</given-names></string-name></person-group>
<article-title>Carbazoles and hydrazone&#x02010;bridged thiazole&#x02010;pyrrole derivatives as new inhibitors of &#x003b1;&#x02010;glucosidase</article-title>. <source>ChemistrySelect</source>. <year>2018</year>;<volume>3</volume>(<issue>27</issue>):<fpage>7921</fpage>&#x02013;<lpage>7925</lpage>.</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Peng</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Gong</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Y.</given-names></string-name></person-group>
<article-title>Synthesis, biological evaluation, and docking studies of novel 5, 6-diaryl-1, 2, 4-triazine thiazole derivatives as a new class of &#x003b1;-glucosidase inhibitors</article-title>. <source>Bioorg Chem</source>. <year>2018</year>;<volume>78</volume>:<fpage>195</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">29587132</pub-id>
</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Dhameja</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kurella</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Uma</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Gupta</surname>
<given-names>P.</given-names></string-name></person-group>
<article-title>Synthesis, in-vitro &#x003b1;-glucosidase inhibition and molecular docking studies of 1, 3, 4-thiadiazole-5, 6-diphenyl-1, 2, 4-triazine hybrids: Potential leads in the search of new antidiabetic drugs</article-title>. <source>J Mol Struct</source> . <year>2023</year>;<volume>1273</volume>(:<fpage>134339</fpage>.</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mahapatra</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Nanda</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Asymmetric synthesis of hydroxy-skipped bishomo-inositols as potential glycosidase inhibitors</article-title>. <source>Tetrahedron: Asymmetry</source>. <year>2010</year>;<volume>21</volume>(<issue>18</issue>):<fpage>2199</fpage>&#x02013;<lpage>2205</lpage>.</mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>AbdelFattah</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Khalifa</surname>
<given-names>MMA</given-names></string-name>, <string-name><surname>El-Sehrawi</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Fayed</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Bayoumi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Said</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Synthesis and anxiolytic activity of some novel 5-oxo-1, 4-oxazepine derivatives</article-title>. <source>LDDD</source>. <year>2011</year>;<volume>8</volume>(<issue>4</issue>):<fpage>330</fpage>&#x02013;<lpage>338</lpage>.</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Ahmed</surname>
<given-names>HY.</given-names></string-name></person-group>
<article-title>Synthesis, characterization and pharmacological evaluation of some new 1, 4-diazepine derivatives as anticancer agents</article-title>. <source>Der Pharma Chem</source>. <year>2016</year>;8(13):<fpage>77</fpage>&#x02013;<lpage>90</lpage>.</mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fathy</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Abd El Salam</surname>
<given-names>HA</given-names></string-name>, <string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Elgamal</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Gouda</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Facile synthesis and in vitro anticancer evaluation of a new series of tetrahydroquinoline</article-title>. <source>Heliyon</source>. <year>2021</year>;<volume>7</volume>(<issue>10</issue>):<fpage>e08117</fpage>.<pub-id pub-id-type="pmid">34693052</pub-id>
</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Othman</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Husseiny</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Abulkhair</surname>
<given-names>HS.</given-names></string-name></person-group>
<article-title>Rationale design, synthesis, cytotoxicity evaluation, and in silico mechanistic studies of novel 1, 2, 3-triazoles with potential anticancer activity</article-title>. <source>New J Chem</source>. <year>2022</year>;<volume>46</volume>(<issue>25</issue>):<fpage>12206</fpage>&#x02013;<lpage>12216</lpage>.</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ammar</surname>
<given-names>YA</given-names></string-name>, <string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Bayoumi</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>Ezz</surname>
<given-names>RR</given-names></string-name>, <string-name><surname>Alsaid</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Soliman</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Ghorab</surname>
<given-names>MM.</given-names></string-name></person-group>
<article-title>New chalcones bearing isatin scaffold: synthesis, molecular modeling and biological evaluation as anticancer agents</article-title>. <source>Res Chem Intermed</source>. <year>2017</year>; <volume>43</volume>(<issue>12</issue>) :<fpage>6765</fpage>&#x02013;<lpage>6786</lpage>.</mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ramsis</surname>
<given-names>TM</given-names></string-name>, <string-name><surname>Ebrahim</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Fayed</surname>
<given-names>EA.</given-names></string-name></person-group>
<article-title>Synthetic coumarin derivatives with anticoagulation and antiplatelet aggregation inhibitory effects</article-title>. <source>Med Chem Res</source>. <year>2023</year>;<volume>32</volume>(<issue>11</issue>):<fpage>2269</fpage>&#x02013;<lpage>2278</lpage>.</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Trinder</surname>
<given-names>P.</given-names></string-name></person-group>
<article-title>Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen</article-title>. <source>J Clin Pathol</source>. <year>1969</year>; <volume>22</volume>(<issue>2</issue>):<fpage>158</fpage>&#x02013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">5776547</pub-id>
</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Orsonneau</surname>
<given-names>J-L</given-names></string-name>, <string-name><surname>Massoubre</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Cabanes</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lustenberger</surname>
<given-names>P.</given-names></string-name></person-group>
<article-title>Simple and sensitive determination of urea in serum and urine</article-title>. <source>Clin Chem</source>. <year>1992</year>;<volume>38</volume>(<issue>5</issue>):<fpage>619</fpage>&#x02013;<lpage>623</lpage>.<pub-id pub-id-type="pmid">1582010</pub-id>
</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saibaba</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Srinivasa Rao</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Dakshina Murty</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Bhaskar</surname>
<given-names>MV.</given-names></string-name></person-group>
<article-title>Method evaluation of an enzymatic method for serum creatinine</article-title>. <source>Indian J Clin Biochem</source>. <year>1997</year>;<volume>12</volume>(<issue>2</issue>):<fpage>139</fpage>&#x02013;<lpage>141</lpage>.<pub-id pub-id-type="pmid">23100881</pub-id>
</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beutler</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Duron</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Kelly</surname>
<given-names>BM.</given-names></string-name></person-group>
<article-title>Improved method for the determination of blood glutathione</article-title>. <source>J Lab Clin Med</source>. <year>1963</year>;<volume>61</volume>(:<fpage>882</fpage>&#x02013;<lpage>888</lpage>.<pub-id pub-id-type="pmid">13967893</pub-id>
</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kei</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method</article-title>. <source>Clin Chim Acta</source>. <year>1978</year>;<volume>90</volume>(<issue>1</issue>):<fpage>37</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">719890</pub-id>
</mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Piyachaturawat</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Poprasit</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Glinsukon</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Wanichanon</surname>
<given-names>C.</given-names></string-name></person-group>
<article-title>Gastric mucosal lesions in streptozotocin-diabetic rats</article-title>. <source>Cell Biol Int Rep</source>. <year>1988</year>;<volume>12</volume>(<issue>1</issue>):<fpage>53</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">2969293</pub-id>
</mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Walker</surname>
<given-names>HK</given-names></string-name>, <string-name><surname>Hall</surname>
<given-names>WD</given-names></string-name>, <string-name><surname>Hurst</surname>
<given-names>JW.</given-names></string-name></person-group>
<article-title>Clinical methods: the history, physical, and laboratory examinations</article-title>. 3rd ed. Boston: Butterworths; <year>1990</year>.</mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McCue</surname>
<given-names>PP</given-names></string-name>, <string-name><surname>Shetty</surname>
<given-names>K.</given-names></string-name></person-group>
<article-title>Inhibitory effects of rosmarinic acid extracts on porcine pancreatic amylase in vitro</article-title>. <source>Asia Pac J Clin Nutr</source>. <year>2004</year>;13(<issue>1</issue>):<fpage>101</fpage>&#x02013;<lpage>106</lpage>.<pub-id pub-id-type="pmid">15003922</pub-id>
</mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Daina</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Michielin</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Zoete</surname>
<given-names>V.</given-names></string-name></person-group>
<article-title>Swissadme: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>42717</fpage>.<pub-id pub-id-type="pmid">28256516</pub-id>
</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Kar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Roy</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Leszczynski</surname>
<given-names>J.</given-names></string-name></person-group>
<part-title>In silico tools and software to predict admet of new drug candidates</part-title>. In: In silico methods for predicting drug toxicity. New York (NY): Springer US; 2022. p. 85&#x02013;115.</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Refai</surname>
<given-names>MY</given-names></string-name>, <string-name><surname>Elazzazy</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Desouky</surname>
<given-names>SE</given-names></string-name>, <string-name><surname>Abu-Elghait</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Alajel</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Alajlan</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Albureikan</surname>
<given-names>MO</given-names></string-name>, <string-name><surname>Nakayama</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Interception of epoxide ring to quorum sensing system in enterococcus faecalis and staphylococcus aureus</article-title>. <source>AMB Express</source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>126</fpage>.<pub-id pub-id-type="pmid">37946062</pub-id>
</mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Thabet</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Abd El-Gilil</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Elsanhory</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Ammar</surname>
<given-names>YA.</given-names></string-name></person-group>
<article-title>Fluorinated thiazole&#x02013;thiosemicarbazones hybrids as potential ppar-&#x003b3; agonist and &#x003b1;-amylase, &#x003b1;-glucosidase antagonists: design, synthesis, in silico admet and docking studies and hypoglycemic evaluation</article-title>. <source>J Mol Struct</source> . <year>2024</year>;<volume>1301</volume>:<fpage>137374</fpage>.</mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Al-Arab</surname>
<given-names>EME</given-names></string-name>, <string-name><surname>Saleh</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Bayoumi</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>Ammar</surname>
<given-names>YA.</given-names></string-name></person-group>
<article-title>Design, synthesis, in silico studies, in vivo and in vitro assessment of pyridones and thiazolidinones as anti-inflammatory, antipyretic and ulcerogenic hits</article-title>. <source>J Mol Struct</source>. <year>2022</year>;<volume>1260</volume>:<fpage>132839</fpage>.</mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Gohar</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Farrag</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Ammar</surname>
<given-names>YA.</given-names></string-name></person-group>
<article-title>Upregulation of bax and caspase&#x02010;3, as well as downregulation of bcl&#x02010;2 during treatment with indeno [1, 2&#x02010;b] quinoxalin derivatives, mediated apoptosis in human cancer cells</article-title>. <source>Arch Pharm</source>. <year>2022</year>;<volume>355</volume>(<issue>5</issue>):<fpage>e2100454</fpage>.</mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bax</surname>
<given-names>BD</given-names></string-name>, <string-name><surname>Chan</surname>
<given-names>PF</given-names></string-name>, <string-name><surname>Eggleston</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Fosberry</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Gentry</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>Gorrec</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Giordano</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Hann</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Hennessy</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hibbs</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Type iia topoisomerase inhibition by a new class of antibacterial agents</article-title>. <source>Nature</source>. <year>2010</year>;<volume>466</volume>(<issue>7309</issue>):<fpage>935</fpage>&#x02013;<lpage>940</lpage>.<pub-id pub-id-type="pmid">20686482</pub-id>
</mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal">Fayed EA, Nosseir ES, Atef A, El Kalyoubi SA. In vitro antimicrobial evaluation and in silico studies of coumarin derivatives tagged with pyrano-pyridine and pyrano-pyrimidine moieties as DNA gyrase inhibitors. Mol Divers. 2022;<volume>26</volume>(<issue>1</issue>):<fpage>341</fpage>&#x02013;<lpage>363</lpage>.</mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Ebrahim</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Fathy</surname>
<given-names>U</given-names></string-name>, <string-name><surname>El Saeed</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Khalaf</surname>
<given-names>WS.</given-names></string-name></person-group>
<article-title>Evaluation of quinoxaline derivatives as potential ergosterol biosynthesis inhibitors: design, synthesis, admet, molecular docking studies, and antifungal activities</article-title>. <source>J Mol Struct</source> . <year>2022</year>;<volume>1267</volume>:<fpage>133578</fpage>.</mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Othman</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Husseiny</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Abulkhair</surname>
<given-names>HS.</given-names></string-name></person-group>
<article-title>The effect of novel synthetic semicarbazone-and thiosemicarbazone-linked 1, 2, 3-triazoles on the apoptotic markers, vegfr-2, and cell cycle of myeloid leukemia</article-title>. <source>Bioorg Chem</source>. <year>2022</year>;<volume>127</volume>:<fpage>105968</fpage>.<pub-id pub-id-type="pmid">35728289</pub-id>
</mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Desouky</surname>
<given-names>SE</given-names></string-name>, <string-name><surname>Abu-Elghait</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Selim</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yousuf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Igarashi</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Abdel-Wahab</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Mohammed Alsuhaibani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sonomoto</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Nakayama</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Secondary metabolites of actinomycetales as potent quorum sensing inhibitors targeting gram-positive pathogens: in vitro and in silico study</article-title>. <source>Metabolites</source>. <year>2022</year>;<volume>12</volume>(<issue>3</issue>):<fpage>246</fpage>.<pub-id pub-id-type="pmid">35323689</pub-id>
</mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Gohar</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Bayoumi</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>Ammar</surname>
<given-names>YA.</given-names></string-name></person-group>
<article-title>Novel fluorinated pyrazole-based heterocycles scaffold: cytotoxicity, in silico studies and molecular modelling targeting double mutant egfr l858r/t790m as antiproliferative and apoptotic agents</article-title>. <source>Med Chem Res</source>. <year>2023</year>;<volume>32</volume>(<issue>2</issue>):<fpage>369</fpage>&#x02013;<lpage>388</lpage>.</mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Ebrahim</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Fathy</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Elawady</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Khalaf</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>Ramsis</surname>
<given-names>TM.</given-names></string-name></person-group>
<article-title>Pyrano-coumarin hybrids as potential antimicrobial agents against mrsa strains: design, synthesis, admet, molecular docking studies, as DNA gyrase inhibitors</article-title>. <source>J Mol Struct</source> . <year>2024</year>;<volume>1295</volume>:<fpage>136663</fpage>.</mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ahangarpour</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Heidari</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Oroojan</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Mirzavandi</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Esfehani</surname>
<given-names>KN</given-names></string-name>, <string-name><surname>Mohammadi</surname>
<given-names>ZD.</given-names></string-name></person-group>
<article-title>Antidiabetic, hypolipidemic and hepatoprotective effects of arctium lappa root&#x02019;s hydro-alcoholic extract on nicotinamide-streptozotocin induced type 2 model of diabetes in male mice</article-title>. <source>Avicenna J Phytomed</source>. <year>2017</year>;<volume>7</volume>(<issue>2</issue>):<fpage>169</fpage>.<pub-id pub-id-type="pmid">28348972</pub-id>
</mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ragab</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Abusaif</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Gohar</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Aboul-Magd</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Fayed</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Ammar</surname>
<given-names>YA.</given-names></string-name></person-group>
<article-title>Development of new spiro [1, 3] dithiine-4, 11&#x02032;-indeno [1, 2-b] quinoxaline derivatives as s. Aureus sortase a inhibitors and radiosterilization with molecular modeling simulation</article-title>. <source>Bioorg Chem</source>. <year>2023</year>;<volume>131</volume>:<fpage>106307</fpage>.<pub-id pub-id-type="pmid">36481380</pub-id>
</mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raghuvanshi</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Singh</surname>
<given-names>KN.</given-names></string-name></person-group>
<article-title>Microwave-assisted synthesis of some novel thiazolidinone and thiohydantoin derivatives of isatins</article-title>. <source>Phosphorus, Sulfur, Silicon Relat Elem</source>. <year>2010</year>;<volume>185</volume>(<issue>11</issue>):<fpage>2243</fpage>&#x02013;<lpage>2248</lpage>.</mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>K Ramshid</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Jagadeeshan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Krishnan</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mathew</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Asha Nair</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Radhakrishna Pillai</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Synthesis and in vitro evaluation of some isatin-thiazolidinone hybrid analogues as anti-proliferative agents</article-title>. <source>MC</source>. <year>2010</year>;<volume>6</volume>(<issue>5</issue>):<fpage>306</fpage>&#x02013;<lpage>312</lpage>.</mixed-citation></ref></ref-list></back></article>